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1.1  Rheumatoid arthritis (RA) 
 
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory, autoimmune disease 
mainly affecting synovial tissues, which can lead to severe morbidity and progressive 
joint destruction resulting in deformations and disability. Other important outcomes 
include extra-articular features and comorbidities, like vasculitis, cardiac disease and 
infections1. RA affects approximately 1% of the adult population and each year, 5 to 50 
per 100.000 persons develop this condition2. Women are affected two to three times 
more often than men. The age of onset in women is usually between 40 and 50 years, 
but it often affects women of childbearing age3. 
 
1.1.1  Etiology of RA 
RA is a multifactorial disease in which genetic and environmental factors interact in the 
etiology. First-degree relatives prevalence rate is 3–5%, which means that the risk of 
developing RA is just a few percent higher when parents or siblings are affected. 
   The risk of developing RA is for approximately 50% attributable to genetic factors4. Of 
these genetic factors the strongest associations are found with certain Human 
Leukocyte Antigen (HLA)-alleles. These HLA-alleles are located on chromosome 6 and 
are involved in antigen presentation and are therefore key molecules in the human 
immune system. 
   The presence of RA associated autoantibodies, like rheumatoid factor (RF) and anti-
citrullinated protein antibody (ACPA) indicates a more severe type of RA, characterised 
by higher disease activity, more joint destruction and extra-articular manifestations5. 
The risk of developing RA is three times more common in smokers than non-smokers6. 
Studies have also shown that the risk of developing ACPA-positive RA is associated with 
a strong gene-environment interaction between smoking and a specific HLA allele. The 
risk of developing RA depends on the magnitude of smoking and genotype7. Besides 
smoking, other environmental factors are thought to be associated with the 
development of RA, including infections, the use of oral contraceptives and parity8,9. 
   In addition to autoantibodies, the release of cytokines, especially pro-inflammatory 
cytokines like tumor necrosis factor-α (TNFα), interleukin-6 (IL-6) and interleukin-1 (IL-1) 
are thought to play an important role in the pathogenesis of RA. Several cells of the 
immune system, including T-cells, B-cells, dendritic cells and macrophages, produce 
and interact with these cytokines10. This all leads to an amplification of the immune 
response, resulting in synovial inflammation and finally joint destruction11. 
  
1.1.2  Treatment of RA 
Fortunately, pharmacological management in RA has greatly improved these last 
decades.  There are several treatment options, depending on the severity of the disease. 
This improvement of RA medication has created a strong reduction of inflammation and 
pain, inhibiting joint destruction and preserving functionality in the majority of RA 
patients. 

Disease-modifying antirheumatic drugs (DMARDs) are the most important treatments in 
RA therapy. The most widely used DMARD is methotrexate, which is the corner stone of 
modern RA-treatment. Other DMARDs commonly used are sulfasalazine and 
hydroxychloroquine. 
   DMARDs may be combined with glucocorticoids like prednisone or dexamethasone. 
Glucocorticoids have anti-inflammatory and immunosuppressant assets. They have 
been shown to influence the course of RA and can therefore be considered DMARDs as 
well. They can be given orally, intramuscularly, or intra-articularly. 
   Since the late 1990s, the so-called biologicals have provided clinically important 
improvement in patients not responding to traditional DMARDs. Biologics are mainly, 
though not exclusively, therapeutic antibodies targeting key molecules of the immune 
system like, pro-inflammatory cytokines, including TNF and IL-612-14.  
 
 
1.2 Pregnancy and RA 
 
While pregnant, the RA disease activity may improve, but contrary to what most people 
think, it does not happen in all women. In literature, the reported improvement of RA 
during pregnancy has declined from 90% to 53%15,16. An explanation for this difference 
might be that past studies have been performed retrospectively, without objective 
information on the disease activity, and without a validated scoring system. 
   The most recent study of De Man et al. did use a prospective cohort, and a well-
validated scoring system for RA disease activity. She found that around 25% of all 
pregnant women have a remission in the third trimester of the pregnancy, despite the 
fact that medication use was reduced during pregnancy15. In general, RA disease activity 
might decrease during pregnancy but will increase postpartum. Almost 50% of the 
women will have a moderate response during pregnancy and more than 35% has a 
moderate flare postpartum. The postpartum flare may be underestimated, because 
medication was often re-started soon after delivery. Medication during pregnancy is 
mostly restricted to prednisone, sulfasalazine and to less extent hydroxychloroquine. 
Until recent, the use of biologicals was inhibited during pregnancy. Nowadays TNF-
blockers have been categorized as “group B” by the Food and Drug Administration 
(FDA). Although only a few reports of congenital malformations have been reported, no 
firm conclusions can be drawn about the safety of anti-TNF therapy during pregnancy17. 
Nevertheless, TNF-blockers are nowadays more often prescribed during pregnancy to 
control active RA. Even if adequate medication is given during pregnancy, becoming 
pregnant can be difficult while suffering from RA. Fertility can be reduced and the risk of 
early miscarriage is higher18,19. 
 
1.2.1  RA and pregnancy outcome 
Pregnancy complications, like gestational hypertension, preeclampsia, but also 
caesarean sections are slightly increased in pregnant women with RA compared to the 
1
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general population. Furthermore pregnancy outcome complications, like low birth 
weight or prematurity are more common in RA20-23. 
   Elevated RA disease activity during pregnancy is associated with a lower birth weight 
of the child independently of many covariates, like medication use, parity, smoking, 
gender of the child, gestational age, maternal age or educational level20. 
   Prednisone use during pregnancy shortens the gestational age in women with RA. De 
Man et al. showed that women with prednisone use deliver (on average) one week 
earlier and had also more often pre-term pregnancies (<37 weeks of gestational age), 
compared with women who did not use prednisone20. Both results concerning 
prednisone use will indirectly lower the birth weight of the child.  
 
 
1.3  Early life determinants associated with adult diseases 
 
Several hypotheses are settled on the idea that certain environmental determinants 
during the fetal and postnatal period are important risk factors for developing adult 
diseases. In the following paragraphs, all known associations of these environmental 
determinants will be described during 3 different periods in early life. Beginning with 
the fetal period (I), followed by the postnatal period during the first year (II), and the 
prepubertal age from 5-10 years (III) (Figure 1.1).  
 
 
 
 
Figure 1.1- Known associations between determinants during the fetal period (I), during the  
first year of life (II), or during prepubertal age (III), and the development of diseases in adulthood. 
  
 
1.3.1  Fetal determinants of diseases in adulthood 
Several environmental determinants are associated with fetal growth deprivation, 
which is often, but not always, manifested in lower birth weight. Besides maternal 
malnutition there are many other maternal environmental determinants, which are 
associated with low birth weight, like smoking, maternal weight, height and body mass 
index (BMI), gestational weight gain and maternal hypertension24-27. Birth weight is 
expressed in birth weight standard deviation scores (birth weight SDS), corrected for 
diseases in adulthood 
	
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gestational age and gender28. Lower birth weight SDS, independent of the reason, is 
associated with diseases in adulthood, like hypertension and cardiovascular disease29-31. 
   Barker et al. were the first to create a hypothesis based on the inverse association 
found between birth weight and several diseases in adulthood32. They hypothesized 
that low intrauterine supply of nutrients, could lead to fetal re-programming33. 
Obviously, the fetus will benefit from these adaptions, because it will survive despite the 
malnutrition. However when the child enters the nutrient-enriched, and in some cases 
nutrient-over enriched world, this re-programming is not necessary anymore and can 
lead to hypertension and coronary heart diseases in adulthood. Importantly, fetal 
malnutrition should not solely be based on the size of the baby at birth. A study done 
on the effect of Dutch famine during World War II showed that maternal malnutrition 
during gestation permanently affected adult health without affecting the birth weight. 
The authors did imply that the adaptations made by the fetus to continue to grow may 
nevertheless have adverse consequences for health in later life like coronary heart 
disease34. 
 
Concerning RA, several maternal RA determinants could potentially lead to low birth 
weight. Rise of RA disease activity often leads to the rise of pro-inflammatory cytokines, 
which might negatively influence the fetal growth as seen in mice-studies35-37. This 
could be an explanation for the low birth weight found when pregnancy is 
accompanied by elevated RA disease activity. Glucocorticoids might also create an 
adverse effect on the fetal programming resulting in impairment of fetal growth38. 
 
1.3.2  First year determinants of diseases in adulthood 
About a decade ago, Singhal and Lucas suggested that not the low birth weight, but 
importantly the acceleration in weight during childhood is associated with increased 
risk for adult diseases later in life39. They assumed that a child is genetically determined 
to grow to its growth potential. When a child is born below his or hers genetic growth 
potential, it can experience postnatal catch-up growth and the tempo of this catch-up is 
essential40.  
   Leunissen et al. specified the hypothesis of Singhal and Lucas by postulating that it is 
not just postnatal growth acceleration, but more importantly it is the fat accumulation 
during childhood, which increases the risk of diseases in adulthood41. They showed that 
fat accumulation during childhood was related to insulin sensitivity, higher levels of 
total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL), and blood 
pressure in early adulthood42-44. Recent studies of Kerkhof et al. specified that is more the 
catch-up growth in weight during the first 3 months of life, which is related to 
unfavorable cardiovascular and metabolic profiles later in life40,41. Catch-up growth is 
defined as a weight gain of more than 0.67 standard SDS during the first year, and is 
called rapid, when the weight gain in first 3 months is more than 0.5 SDS40,41,45.  
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Concerning RA, elevated RA disease activity and RA medication use are related, directly 
or indirectly, with lower birth weight of the child20. Catch-up growth is therefore 
unavoidable, but it is unknown in which time and tempo these children experience 
catch-up growth in the first year of life.  
 
1.3.3  Prepubertal determinants of diseases in adulthood 
High amount of total fat mass during childhood tends to track into adulthood, meaning 
that children with high body mass index (BMI) will become adults with higher BMI, 
thereby increasing the risk for cardiovascular disease (CVD) or Type II Diabetes Mellitus 
(T2DM) in adulthood46,47. Abdominal distribution of body fat is associated with insulin 
resistance and dyslipidemia48. 
   A cluster of cardiovascular risk factors that have been shown to predict the 
development of CVD and T2DM in adulthood is called the metabolic syndrome. The 
International Diabetes Federation has defined this metabolic syndrome for children49. 
Insulin resistance is a precursor of the metabolic syndrome and is evaluated using the 
Homeostasis Model of Assessment Insulin Resistance (HOMA-IR) and the level of serum 
adiponectin in the child. 
   Animal studies showed a reduced, negative feedback of the hypothalamic-pituitary-
adrenal (HPA) axis when exposed to synthetic glucocorticoids in utero, which led to 
elevated blood pressure and glucocorticoid levels in adult offspring50. Studies postulate 
that synthetic glucocorticoids can influence the activity of the fetal HPA axis especially 
in the early stage of pregnancy, when the placenta has not been fully developed51,52. 
Furthermore, in adults increased total cortisol exposure is associated with 
athoresclerosis of the carotid arteries53.  
   The risk for adult disease can be evaluated by assessing the body composition of the 
prepubertal child, the presence of metabolic syndrome (MetS) including insulin 
sensitivity or by the presence of elevated daily cortisol levels in the children. Body 
composition is assessed by anthropometric measurement including weight, height, skin 
folds, waist and hip circumferences. The total amount and distribution of the fat mass 
can be assed using a DXA-scan. 
 
Concerning RA, previous studies have suggested that in utero exposure to 
glucocorticoids can lead to persistently increased glucocorticoid effect throughout 
adulthood leading to diseases in adulthood like CVD and T2DM51. This fetal exposure to 
prednisone could influence the fetal programming of the unborn child. This could be by 
‘re- programming’ the fetal HPA-axis. It is unknown if this ‘re- programming’ happens in 
pregnant women with RA and if the consequences are still present in their offspring at 
prepubertal age. Due to the fact that elevated RA disease activity can create fetal 
growth restriction it could also create similar consequences. 
 
 
 

1.4  Aims of the study 
 
In the FEPRA-study (FEtal Programming in Rheumatoid Arthritis) we explored the 
association between RA related variables during pregnancy, found in the PARA-study 
(Pregnancy-induced Amelioration of Rheumatoid Arthritis), and the growth and 
development of the offspring until prepubertal age. All subjects of the FEPRA-study are 
children born to women who participated in the PARA-study. The designs of the two 
studies are described in Appendix A.  
   The main aim of the FEPRA-study was to assess if RA variables during pregnancy, like 
RA disease activity, medication use and the presence of RA autoantibodies, are 
associated with early determinants of diseases in adulthood. The early life determinants 
of diseases in adulthood can be measured at birth (I), during the first year of life (II), or at 
prepubertal age with a range from 5 until 10 years old (III) (Figure 1.2). At these time 
points different outcomes were measured, but all outcomes added to the main aim, 
trying to assess risk factors for future diseases in adulthood and then relating these risk 
factors to maternal RA disease activity and medication use during pregnancy.  
 
 
 
 
Figure 1.2 -This thesis aims to describe associations between maternal RA determinants 
throughout pregnancy, and determinants of adult disease at birth (I), during the first year of life 
(II), or at prepubertal age (III). 
 
 
I) At birth  
- Do RA variables during pregnancy, negatively influence the birth weight SDS of the child? 
To investigate whether the RA associated cytokines IL-10, IL-6 and TNFα, in pregnant 
women with RA, influence the fetal growth resulting in lower birth weight SDS of the 
child. 
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prepubertal age. Due to the fact that elevated RA disease activity can create fetal 
growth restriction it could also create similar consequences. 
 
 
 

1.4  Aims of the study 
 
In the FEPRA-study (FEtal Programming in Rheumatoid Arthritis) we explored the 
association between RA related variables during pregnancy, found in the PARA-study 
(Pregnancy-induced Amelioration of Rheumatoid Arthritis), and the growth and 
development of the offspring until prepubertal age. All subjects of the FEPRA-study are 
children born to women who participated in the PARA-study. The designs of the two 
studies are described in Appendix A.  
   The main aim of the FEPRA-study was to assess if RA variables during pregnancy, like 
RA disease activity, medication use and the presence of RA autoantibodies, are 
associated with early determinants of diseases in adulthood. The early life determinants 
of diseases in adulthood can be measured at birth (I), during the first year of life (II), or at 
prepubertal age with a range from 5 until 10 years old (III) (Figure 1.2). At these time 
points different outcomes were measured, but all outcomes added to the main aim, 
trying to assess risk factors for future diseases in adulthood and then relating these risk 
factors to maternal RA disease activity and medication use during pregnancy.  
 
 
 
 
Figure 1.2 -This thesis aims to describe associations between maternal RA determinants 
throughout pregnancy, and determinants of adult disease at birth (I), during the first year of life 
(II), or at prepubertal age (III). 
 
 
I) At birth  
- Do RA variables during pregnancy, negatively influence the birth weight SDS of the child? 
To investigate whether the RA associated cytokines IL-10, IL-6 and TNFα, in pregnant 
women with RA, influence the fetal growth resulting in lower birth weight SDS of the 
child. 
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II) During the first year of life 
- Do RA variables during pregnancy, negatively influence the tempo first year growth? To 
examine the influence of RA disease activity, medication use and the presence of RA 
associated autoantibodies during pregnancy, on the growth tempo of the child in the 
first year of life.  
 
III) At prepubertal life 
- Do RA variables during pregnancy, influence the body composition of the prepubertal 
offspring? To investigate if RA associated variables during pregnancy, like RA disease 
activity and medication use, increase the prevalence of early risk factors of diseases in 
adulthood at the prepubertal age. The early risk factors were assessed based on the 
body composition of the child, including the total amount and distribution of the fat 
mass in the body. It was also assessed on the prevalence of metabolic syndrome (MetS).   
 
- Do RA variables during pregnancy, influence the insulin resistance of the prepubertal 
offspring? Insulin resistance was assed using the HOMA-IR. Furthermore, early risk 
factors were assessed based on lipid profiles, including the level of serum adiponectin 
of the offspring.  
 
- Do RA variables during pregnancy, influence bone mineral density of the prepubertal 
offspring? To investigate if the bone mineral density of the children differs from the 
normal population, because both elevated disease activity and prednisone use are 
involved in developing low bone mineral density in patients54,55. 
 
- Do RA variables during pregnancy, influence the cortisol levels of the prepubertal offspring?  
Finally, to explore whether maternal prednisone use during pregnancy had an influence 
on the fetal hypothalamic–pituitary–adrenal (HPA) axis by assessing the daytime 
cortisol levels of the prepubertal offspring. 
 
 
1.5  Design of the studies 
 
1.5.1  PARA-study  
The PARA-study (Pregnancy-induced Amelioration of Rheumatoid Arthritis) is the 
world’s largest prospective, nationwide cohort study on pregnancy and RA, which 
started in 2002 and ended in 201015. The main purpose of this study was to observe the 
mutual interaction between RA disease activity and pregnancy, including pregnancy 
outcome. In addition, it was set up to examine pathogenic mechanisms underlying this 
mutual interaction. 
In the PARA-study women were recruited by their rheumatologist and were eligible 
for inclusion if they had a pregnancy wish or when they were already pregnant. All 
women met the American College of Rheumatology 1987 revised criteria for RA56,57. 

Patients were visited at their home address at preconception, 3 times during pregnancy 
and 3 times postpartum. During every visit, a physical examination was performed, 
medication use was collected and RA disease activity calculated using the DAS28CRP, a 
well-validated tool for RA disease activity during pregnancy20. This tool calculates the RA 
disease activity score by examining 28 joints using 2 variables per joint: number of 
swollen joints and number of tender joints, and measuring the serum C-reactive protein 
(CRP) level62.  
   Birth weight was expressed in birth weight standard deviation scores (birth weight 
SDS), corrected for gestational age and using a gender specific formula28.  
   Medication use during pregnancy was restricted to prednisone, sulfasalazine and 
hydroxychloroquine. The following table is and indication of the medication used in the 
PARA study15. 
 
 
Table 1.1 – Indication of the medication used in the PARA-study (de Man et al.15). 
 ever used 
n=84 
pre-pregnancy 
n=41 
1st trim  
n=84 
2nd trim 
n=84 
3rd trim  
n=84 
 n(%) n(%) n(%) n(%) n(%) 
prednisone (oral) 33 (39) 16 (39) 30 (36) 30 (36) 29 (35) 
sulfasalazine 65 (77) 17 (41) 26 (31) 28 (33) 27 (32) 
hydroxychloroquine 31 (37) 2 (5) 2 (2) 3 (4) 2 (2) 
methotrexate 46 (55) 0 (0) 0 (0) 0 (0) 0 (0) 
leflunomide 4 (5) 0 (0) 0 (0) 0 (0) 0 (0) 
biologicals 10 (12) 0 (0) 0 (0) 0 (0) 0 (0) 
no medication n/a 7 (17) 22 (26) 29 (35) 29 (35) 
      
Abbreviations: trim: trimester 
 
*This table is kindly provided by dr Y.A. de Man and has been published before15 
 
 
   The medical treatment during pregnancy was adapted in some women due to the fact 
that RA disease activity declined during pregnancy. The median oral dose of prednisone 
in the first trimester was 6.00 mg/day with an interquartile range (IQR) of 1.0 to 10.0 
mg/day. In the third trimester the median dose was 5.00 mg/day (IQR = 4.4-10.0 
mg/day). Other medication included sulfasalazine, sometimes in combination with 
prednisone. The median (IQR) sulfasalazine dose was 2000 (500-4000) mg/day 
throughout the entire pregnancy.  
   One of the main conclusions from the PARA-study was that elevated RA disease 
activity during pregnancy is associated with a lower birth weight and that prednisone 
shortens the gestational age20. These conclusions served as the basis of the FEPRA-
study, which resulted in this doctoral dissertation. 
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1.5.2 FEPRA-study  
After participating in the PARA-study, all mothers were contacted by mail and phone to 
participate in the FEPRA-study (FEtal Programming in Rheumatoid Arthritis). Growth 
charts of the children were collected from birth onwards. Information was obtained out 
of the growth booklet (Dutch: groeiboekje) or records of the infant welfare centre 
(Dutch; consultatiebureau). 
   When the child reached the age of 5 years, both parents and the child were invited to 
visit the Sophia Children’s Hospital in Rotterdam. Less than one week before the visit 
salivary sampling was completed at home. Sampling was done using polyesther swabs 
during four time-points: at awakening, 30 minutes after awakening, afternoon, before 
going to bed. The parents recorded the sampling times immediately after completing 
saliva sampling. At the hospital the swabs were centrifuged and stored at -20oC until 
measured. Salivary sampling is a non-invasive technique in domestic setting, without 
the need of repeated blood samples. Saliva cortisol levels are highly correlated with 
serum levels and there advantage is that the cortisol level is not contaminated with 
stress resulting from needle or hospital59-61. In the present thesis, saliva cortisol samples 
were used to assess the hypothalamic-pituitary-adrenal axis activity. 
   During the visit at the hospital, several characteristics of child and parents were 
determined like, weight, height, head circumference and blood pressure. The 
anthropometric data of the child were extended with sitting height and circumference 
of arm, waist and hip and also included skin folds (triceps, biceps, subscapular and 
suprailiac) measured with a Holtain caliper. All values were transformed to standard 
deviation scores (SDS) for age and gender according to Dutch reference values64,65, 
using the Growth Analyser (version4.0; Growth analyser BV, Rotterdam, the Netherlands, 
www.growthanalyser.org). 
   Fasting blood samples of the child were taken to measure glucose fasting levels, 
insulin fasting levels, high-density lipoprotein fasting levels, triglycerides fasting levels, 
total cholesterol and adiponectin concentrations.  
   All children underwent a Dual-Energy X-ray Absorptiometry (DXA)-scan to assess bone 
mineral density and body composition58. The radiation dose during a DXA scan is 
approximately 1/10 of a chest X-ray58. 
 
 
1.6  Outline of this thesis 
 
This thesis gives a detailed description of RA associated variables during pregnancy, 
namely prednisone use and RA disease activity, and the consequences of these 
variables on offspring. Chapter 1 gives an introduction in the topics described in this 
thesis. Chapter 2 defines the association between maternal serum cytokine levels in the 
pregnant women with RA, with birth weight SDS of the child. Chapter 3 illustrates the 
postnatal growth pattern in the first 2 years of the children, born from mother with RA. 
In Chapter 4 the associations between RA medication plus RA disease activity and the 

bone mineral density of the child is described. Chapter 5 investigates whether 
prednisone or elevated RA disease activity in pregnant women with RA influence the 
body composition of their offspring, or increase the presence of metabolic syndrome. 
Chapter 6 focuses on signs of insulin resistance at the children focusing on 3 alternative 
outcomes to evaluate the insulin resistance: body fat distribution, Homeostasis Model 
of Assessment Insulin Resistance (HOMA-IR), and level of serum adiponectin. The 
objective of Chapter 7 was to investigate whether prednisone-exposure in utero 
influences the cortisol levels of prepubertal children. In Chapter 8 we discuss the 
significance and clinical implications of the results found. It debates the conclusion in 
the light of current literature, and gives recommendations for future research. In 
Chapter 9, a summary of the dissertation is given in English and in Chapter 10 a 
summary of the dissertation is given in Dutch. The addendum of this thesis contains a 
list of abbreviations and a few words about the author. It further includes the PhD 
portfolio, the list of co-authors and affiliations and the acknowledgments.  
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ABSTRACT 
 
Background  
High rheumatoid arthritis (RA) disease activity during pregnancy is associated with a 
lower birth weight. Active RA is characterised by high circulating levels of cytokines, 
which can mediate placental growth and remodelling. 
 
Objectives  
To assess the influence of maternal serum cytokine levels on birth weight in RA 
pregnancy. 
 
Methods  
This study is embedded in the PARA Study, a prospective study on RA and pregnancy. In 
the present study, 161 pregnant women with RA and 32 healthy pregnant women were 
studied. The main outcome measures were birth weight SD score (birth weight SDS) in 
relation to maternal serum levels of interleukin-10 (IL- 10), interleukin-6 (IL-6) and 
tumour necrosis factor-α (TNFα) at three different time points: preconception and 
during the first and third trimester. Single-nucleotide polymorphisms (SNPs) in the 
corresponding cytokine genes were also studied. 
 
Results  
During the first trimester, IL-10 was detectable in 16% of patients with RA, IL-6 in 71%, 
and TNFα in all patients with RA. Mean birth weight SDS of children born to mothers 
with RA was higher when IL-10 level was high compared with low (difference=0.75; 
p=0.04), and lower when IL-6 was high compared with low (difference=0.50; p<0.01) in 
the first trimester. No correlation was seen at the other time points studied or with 
TNFα. Cytokine levels were not related to their corresponding SNPs. 
 
Conclusions  
Maternal IL-10 and IL-6 levels are associated with fetal growth in RA. In the first 
trimester, high IL-10 levels are associated with higher birth weight SDS, and high IL-6 
levels are associated with lower birth weight SDS, even after correction for disease 
activity. 

INTRODUCTION 
 
In normal pregnancies, cytokine levels are not always detectable, but active rheumatoid 
arthritis (RA) is characterised by high serum levels of cytokines. RA is a chronic, systemic 
autoimmune disease in which cytokines play a crucial role in the disease activity1. 
   High maternal cytokines can initiate and intensify the cascade of inflammatory 
cytokine production during normal pregnancy, resulting in maldevelopment of the 
placenta leading to spontaneous abortion, intrauterine growth restriction (IUGR) or 
preterm delivery2. Aberrant maternal cytokine levels have been reported in several 
perinatal complications, such as pre-eclampsia3, pre-term delivery4 and threatened 
miscarriages5. 
   It has been shown that high RA disease activity is associated with a lower birth 
weight6. High disease activity can be related to high cytokine levels, but it is not known 
if high cytokine levels influence birth weight. A lower birth weight, even within the 
normal range, might be a risk factor for perinatal complications and is associated with 
developmental delay, cardiovascular disease, hypertension, non-insulin-dependent 
diabetes mellitus and neuropsychiatric disorder in adulthood7-9. 
   In the present study, three different points in time were chosen to evaluate cytokine 
levels: pre-conception, first and third trimester. If high circulating cytokines influence 
placentation and even implantation of the fetus, as mice studies have emphasised10, the 
focus should be on the beginning of the pregnancy. The third trimester was chosen 
because of the rapid growth and maturation of the fetus in that period. Interleukin-10 
(IL-10), interleukin-6 (IL-6) and tumour necrosis factor-α (TNFα) were studied, because 
they are implicated in the pathogenesis of RA as well as in pregnancy outcome 
1,5,11-13.  
   Certain functional variations due to single- nucleotide polymorphisms (SNPs) in the 
genes of IL-10, IL-6 and TNFα have been shown to influence cytokine levels, increase the 
risk of developing RA, and be associated with preterm birth and increased risk of pre-
eclampsia14. In our study, these specific SNPs were taken into account. 
   We hypothesised that high maternal serum levels of cytokines influence fetal growth 
during pregnancy in women with RA. Describing these effects should lead to a better 
understanding of the function of cytokines during pregnancy and their influence on 
pregnancy outcome. 
 
 
SUBJECTS & METHODS 
 
Study population 
This study is embedded in the PARA-study (Pregnancy-induced Amelioration of 
Rheumatoid Arthritis), a prospective, nationwide cohort study in pregnant women with 
RA15. For present analyses, information was obtained at preconception (range of 3 
month-1 year before conception) and during first trimester (range 8-12 weeks of 
gestation) and the third trimester (range 28-32 weeks of gestation). Preconception was 
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Study population 
This study is embedded in the PARA-study (Pregnancy-induced Amelioration of 
Rheumatoid Arthritis), a prospective, nationwide cohort study in pregnant women with 
RA15. For present analyses, information was obtained at preconception (range of 3 
month-1 year before conception) and during first trimester (range 8-12 weeks of 
gestation) and the third trimester (range 28-32 weeks of gestation). Preconception was 
Chapter 2
28
defined as actively trying to become pregnant after stopping all teratogenic RA 
medication for at least 3 months. Women were recruited by their rheumatologist and 
were eligible for inclusion if they wished to become pregnant or when they were 
already pregnant, but no further than the second trimester. All women met the 
American College of Rheumatology 1987 revised criteria for RA16. Only singleton 
pregnancies of Caucasian women, who delivered a child without congenital 
deformities, were included17. A total of 162 participants were enrolled, of whom 73 were 
seen at preconception, 139 were visited in the first trimester, and data for 158 were 
available for the third trimester. One patient was excluded from the study because of 
having breast cancer during her pregnancy. Therefore, 161 Caucasian women with RA 
were eligible for the study. 
   Since serum cytokine levels may depend on the detection method, a comparison 
group was included to observe the main outcome in a normal population. Thirty-two 
healthy pregnant Caucasian women without an adverse obstetric history were 
recruited. They were visited at the same time points and had the same assessments and 
laboratory tests as the pregnant women with RA. The PARA study was approved by the 
Medical Ethics Committee, Erasmus MC (Rotterdam, The Netherlands). 
 
Pregnancy outcome 
Data on pregnancy outcome included birth weight, gestational age at delivery, and 
gender of the child. Birth weight was expressed as birth weight SD scores (birth weight 
SDS), corrected for gestational age and gender18. 
 
Factors associated with pregnancy outcome 
Clinical characteristics were collected by medical record and physical examination. They 
included maternal age, gynaecological history, medication use and smoking habits. 
   At every time point, RA Disease Activity Score (DAS28) was calculated by examining 28 
joints using 2 variables per joint: number of swollen joints, number of tender joints, and 
measuring serum C-reactive protein (CRP) level19. It has been shown that RA disease 
activity is most reliably assessed with this modality of the DAS28 during pregnancy20. 
CRP levels were directly measured using the Tina-Quant CRP Immunological Test 
System (Roche Diagnostics, Almere, The Netherlands). After centrifugation, all samples 
were frozen at −80°C until assayed. Serum levels of IL-10, IL-6 and TNFα were 
determined using the immunoassay system, IMMULITE 1000 (Siemens Healthcare 
Diagnostics, Breda, The Netherlands). The intra-run/inter-run mean±variation coefficient 
was: IL-10, 27.7±4.6%/23.35±5.4%; IL-6, 105.6±4.9%/ 87.67± 6.1%; TNFα, 105.6±4.9% 
/89.5±3.8%. The lower limit of quantification was IL-10, 5.0; IL-6, 2.0; TNFα, 2.0. All 
cytokine levels are presented in pg/ml. 
 
Genetic factors associated with cytokine levels 
SNPs selected were either proven to be functional in relation to cytokine level or 
associated with RA or pregnancy outcome. In addition, a minor allele frequency of >0.10 
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in the National Center for Biotechnology Information database was required21. Eight 
SNPs were selected, which all proved to be located in the promoter region of the 
cytokine gene. Blood for DNA isolation was available for 134 patients. 
   On chromosome 1, the IL10 gene has three SNPs known to influence serum IL-10 
levels: rs1800871, rs1800872 and rs180089614. The last of these SNPs increases the risk of 
developing RA when it is a homozygous AA carrier22. 
   On chromosome 7, the IL6 gene has two SNPs, rs1800795 and rs1800797, which are 
known to influence serum IL-6 levels and are associated with risk of preterm birth 23. 
   On chromosome 6, the TNFα gene has three SNPs known to influence serum TNFα 
levels: rs1800630, rs1800629 and rs179972424. To evaluate rs1800630, we took a tagging 
SNP in high linkage disequilibrium (rs2844482; r2 =1.00)25. All genetic testing was done 
using a Sequenom® iPLEX. 
 
Data analysis  
Descriptive statistics are presented as numbers, percentages, means and SDs. Spearman 
rank correlation coefficients were calculated to evaluate correlations between disease 
activity and serum levels of cytokines. 
   Univariate linear regression analyses were performed, with birth weight SDS as 
dependent variable and maternal serum levels of IL-10, IL-6 and TNFα at preconception 
and in the first and last trimester as independent variables. Even after trans- formation, 
cytokine levels were not normally distributed and were therefore dichotomised 
according to their median: 0 when the level was lower or equal to the median (low), and 
1 when the level was higher than the median (high). When the median was 0, the 
median of the detectable cytokine levels was taken. Depending on the trimester, IL-10 
was measurable in 11–16% of the women with RA (table 1). Consequently, the median 
of the measurable levels was taken. For IL-6 and TNFα, the median of all levels was 
taken. To describe the association between maternal cytokine level and birth weight 
SDS, RA disease activity was addressed as a confounder because it is known to influence 
birth weight and cytokine levels26. Other potential confounders are maternal age, 
smoking habit, and use of prednisone and/or sulfasalazine27. A multivariate regression 
model (analysis of covariance) with backward selection was used, and all potential 
confounders with highest p value were eliminated from the model until all p values 
were less than 0.2. 
   For SNP genotype distributions, significant departure from Hardy–Weinberg 
equilibrium was calculated using the χ2 test. The Lewontin’s D prime (D0) and 
correlation coefficient (r2) were calculated to assess the presence of linkage 
disequilibrium (r2≥0.8). The Kruskal–Wallis rank test was used to determine the 
difference in serum cytokine levels within the three genotype groups. Linear regression, 
based on allele dose, was per- formed, with birth weight SDS as dependent variable and 
genotype groups as independent variable. All statistical analyses were performed using 
Stata software (V.12.0 for Windows). All SNP analyses were performed using Haploview 
(V.4.2 for Windows) with the CEU trio as reference. 
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levels: rs1800630, rs1800629 and rs179972424. To evaluate rs1800630, we took a tagging 
SNP in high linkage disequilibrium (rs2844482; r2 =1.00)25. All genetic testing was done 
using a Sequenom® iPLEX. 
 
Data analysis  
Descriptive statistics are presented as numbers, percentages, means and SDs. Spearman 
rank correlation coefficients were calculated to evaluate correlations between disease 
activity and serum levels of cytokines. 
   Univariate linear regression analyses were performed, with birth weight SDS as 
dependent variable and maternal serum levels of IL-10, IL-6 and TNFα at preconception 
and in the first and last trimester as independent variables. Even after trans- formation, 
cytokine levels were not normally distributed and were therefore dichotomised 
according to their median: 0 when the level was lower or equal to the median (low), and 
1 when the level was higher than the median (high). When the median was 0, the 
median of the detectable cytokine levels was taken. Depending on the trimester, IL-10 
was measurable in 11–16% of the women with RA (table 1). Consequently, the median 
of the measurable levels was taken. For IL-6 and TNFα, the median of all levels was 
taken. To describe the association between maternal cytokine level and birth weight 
SDS, RA disease activity was addressed as a confounder because it is known to influence 
birth weight and cytokine levels26. Other potential confounders are maternal age, 
smoking habit, and use of prednisone and/or sulfasalazine27. A multivariate regression 
model (analysis of covariance) with backward selection was used, and all potential 
confounders with highest p value were eliminated from the model until all p values 
were less than 0.2. 
   For SNP genotype distributions, significant departure from Hardy–Weinberg 
equilibrium was calculated using the χ2 test. The Lewontin’s D prime (D0) and 
correlation coefficient (r2) were calculated to assess the presence of linkage 
disequilibrium (r2≥0.8). The Kruskal–Wallis rank test was used to determine the 
difference in serum cytokine levels within the three genotype groups. Linear regression, 
based on allele dose, was per- formed, with birth weight SDS as dependent variable and 
genotype groups as independent variable. All statistical analyses were performed using 
Stata software (V.12.0 for Windows). All SNP analyses were performed using Haploview 
(V.4.2 for Windows) with the CEU trio as reference. 
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Table 2.1 - Patient and Pregnancy Characteristics. 
 
RA patients  
(n= 161) 
Reference group  
(n=32) 
Patient Characteristics mean (SD)  mean (SD)  
   Age at delivery in years 32.53 (3.66) 32.11 (4.40) 
   RA duration at delivery in years 7.90 (6.50) na 
   Parity  %   %   
nulliparous 
multipara 
missing 
50.3  
48.5 
1.2 
44 
56 
na 
   Smoking during pregnancy 4 (n=154) 10 (n=32) 
DAS28 at different time points,    
        pre-conception 
trimester 1  
trimester 3  
3.73 (0.98) (n=73) 
3.71 (1.11) (n=139) 
3.40 (1.13) (n=158) 
na 
na 
na 
Use of Medication at different time   
   Prednisone % (n)  
pre-conception 
trimester 1  
trimester 3  
29 (n=21) 
27 (n=37) 
26 (n=42) 
na 
na 
na 
    Sulfasalazine   
pre-conception 
trimester 1  
trimester 3  
21 (n=15) 
17 (n=24) 
17 (n=27) 
na 
na 
na 
    Both   
pre-conception 
trimester 1  
trimester 3  
12 (n=9) 
11 (n=15) 
9 (n=15) 
na 
na 
na 
Pregnancy outcome mean (SD) mean (SD) 
   Birth weight in kilograms 3.390 (0.58) 3.492 (0.45) 
   Gestational age in weeks, 39.4 (1.80) 40.1 (1.45) 
   Birth weight SDS -0.004 (1.09) -0.020 (0.96) 
   Gender of child male, % 57 56  
Birth weight SDS in groupsa (trimester 3)   
   DAS28 ≤ 3.2 (low) 
   DAS28 3.2-5.1 (intermediate) 
   DAS28 > 5.1 (high) 
0.164 (0.99) (n=72) 
-0.119 (1.07) (n=74) 
-0.390 (1.53) (n=12) 
 
   
Cytokine levels at different time points c 
 
median (IQR) 
(detectable %) 
median (IQR)  
(detectable %) 
   IL-10: pre-conception 
   IL-10: trimester 1  
   IL-10: trimester 3  
6.01 (5.45-10.4) (13%)b 
9.61 (5.95-15.9) (16%)b 
9.56 (6.21-12.6) (11%)b 
na 
8.16 (5.72-9.07) (9%)b 
6.45 (6.45-13.9) (9%) b 
   IL-6: pre-conception 
   IL-6: trimester 1  
   IL-6: trimester 3  
4.84 (0.00-12.8) (76%) 
2.91 (0.00-7.57) (71%) 
2.09 (0.00-3.98) (51%) 
na 
0.00 (0.00-2.09) (28%) 
0.00 (0.00 to 2.23) (32%) 
   TNFα: pre-conception 
   TNFα: trimester 1  
   TNFα: trimester 3 
10.5 (8.78-12.2) (100%) 
14.2 (11.8-17.9) (100%) 
11.0 (9.31-13.1) (100%) 
na 
9.87 (8.59-12.0) (100%) 
10.00 (8.56-13.15) (100%) 
Abbreviations: RA, rheumatoid arthritis; na, not applicable; DAS28, RA disease Activity Score in 28 joints 
with CRP levels; SDS, Standard Deviation Score; a disease groups according to EULAR criteria; b Median 
of the detectable levels was taken; c All cytokine levels are expressed as pg/ml. 
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RESULTS 
 
Participants 
Mean maternal age at delivery was 32.5 years, and mean RA disease duration was 7.9 
years (Table 2.1). Fewer than 4% of the subjects smoked, and 52–55% used medication 
during pregnancy. Medication use was restricted to prednisone, sulfasalazine or both 
(Table 2.1). None of the pregnant women used methotrexate or biologic agents before 
conception or during pregnancy. Only a minority of patients (n=3) used 
hydroxychloroquine.  
   Mean birth weight SDS was -0.004 SD (1.09). As expected, higher DAS28 was 
associated with a lower birth weight6. During the third trimester, an increase of 1 point 
in DAS28 correlated with a decrease in birth weight SDS of 0.21 (p= 0.005). 
   The 32 healthy pregnant women had a mean age of 32.1 years and 10% (3/32) 
smoked. Mean birth weight SDS was -0.02 SD (0.96) (Table 2.1). 
 
Cytokine levels & birth weight 
All cytokine levels correlated strongly with each other and the levels at different time 
points were related (Table 2.2). Levels of IL-10, IL-6 but not TNFα, correlated with DAS28 
during all time points (first trimester shown in Table 2.2). Cytokine levels in healthy 
women showed similar correlations, but these were not significant, because of the small 
sample (data not shown). 
 
 
Table 2.2 - Correlation of cytokine levels, DAS at first trimester and other time point in RA patients. 
 
Correlation during 1st  trimester                
Spearman's rho (p-value) 
Correlation during 1st and other time point 
Spearman's rho (p-value) 
Levels IL-10 IL-6 TNFα Before pregnancy Third Trimester 
IL-10 - - - 0.29 (0.02) 0.49 (<0.001) 
IL-6 0.32 (<0.001) - - 0.51 (<0.001) 0.54 (<0.001) 
TNFα 0.35 (<0.001) 0.24 (0.004) - 0.20 (0.10) 0.45 (<0.001) 
DAS28 0.25 (0.004) 0.40 (<0.001) 0.03 (0.71) 0.48 (<0.001) 0.56 (<0.001) 
      
Abbreviations: DAS28, disease activity score of rheumatoid arthritis in 28 joints with CRP levels 
 
 
   As stated above, cytokine levels were defined as low when the level was lower or 
equal to the median, and high when the level was higher than the median. When the 
median was 0, the median of the detectable cytokine levels was taken. 
   During first trimester, IL-10 was detectable in 16% of the patients with RA (n=21). 
According to our definition IL-10 was high in 7% of the RA patients (n=10) and low in 
93% (n=129). The mean birth weight SDS was 0.55 in the high-IL-10 group and −0.07 in 
the low-IL-10 group. The high-IL-10 group was associated with higher birth weight SDS 
than the low-IL-10 group (difference 0.75, p=0.040) after adjustment for confounders 
(Table 2.3a). No such effect was seen at preconception or in the third trimester. 
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   As stated above, cytokine levels were defined as low when the level was lower or 
equal to the median, and high when the level was higher than the median. When the 
median was 0, the median of the detectable cytokine levels was taken. 
   During first trimester, IL-10 was detectable in 16% of the patients with RA (n=21). 
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than the low-IL-10 group (difference 0.75, p=0.040) after adjustment for confounders 
(Table 2.3a). No such effect was seen at preconception or in the third trimester. 
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Table 2.3a - Effect of dichotomised (high vs. low) cytokine levels (crude-adjusted) on birth weight SDS 
First trimester (n=139) 
 Crude Adjusted 
 ß (95% CI) p-value ß (95% CI) p-value 
IL-10 0.62 (-0.08;1.32) 0.08 0.75 (0.04;1.46) 0.04 
DAS28 
 
-0.13 (-0.29;0.03) 0.11 
maternal age 0.02 (-0.01;0.04) 0.10 
prednisone -0.28 (-0.68; 0.12) 0.17 
     
IL-6 -0.47 (-0.83;-0.11) 0.01 -0.50 (-0.87;-0.13) <0.01 
DAS28  - - 
maternal age 0.01 (-0.00;0.01) 0.10 
     
TNFα  0.04 (-0.34;0.41) 0.85 - - 
DAS28 
 
- - 
maternal age - - 
prednisone -0.24 (-0.56;0.08) 0.15 
    
Abbreviations: DAS28, disease activity score of rheumatoid arthritis in 28 joints with CRP levels - not
included in the model because p>0.2; Adjusted for RA disease activity, maternal age, smoking,
prednisone use and sulfasalazine use 
 
 
During the first trimester, IL-6 was detectable in 71% of the patients with RA (n=95). It 
was high in 48% (n=67). The mean birth weight SDS was −0.26 in the high-IL-6 group 
and 0.21 in the low-IL-6 group. The high-IL-6 group was associated with lower birth 
weight SDS (difference −0.50, p=0.009) after adjustment for confounders (Table 2.3a). 
No such effect was seen at the other time points (Table 2.3b). When the effects of IL-6 
and IL-10 were analysed simultaneously, the effect was even more pronounced, 
resulting in a birth weight SDS increase of 0.82 for high IL-10 and a decrease of 0.58 for 
high IL-6 (Table 2.3c). 
   High levels of TNFα had no effect on birth weight SDS at any time point (Table 2.3a/b). 
Cytokine levels did not influence the gestational age (data not shown). In the reference 
group, cytokine levels were low and often undetectable (Table 2.1). Numbers were too 
small to allow statistical analysis 
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Table 2.3b - Effect of dichotomised (high vs. low) cytokine levels (crude-adjusted) on birth weight SDS 
Third trimester (n=161) 
 Crude Adjusted 
 ß (95% CI) p-value ß (95% CI) p-value 
IL-10 -0.21 (-0.94;0.53) 0.58 - - 
DAS28 
 
-0.21 (-0.35;-0.07) <0.01 
maternal age 0.02 (0.01;0.04) <0.01 
prednisone - - 
     
IL-6 -0.23 (-0.57;0.11) 0.19 - - 
DAS28  -0.22 (-0.35;0.08) <0.01 
maternal age 0.02 (0.01;0.37) <0.01 
     
TNFα  0.09 (-0.26;0.43) 0.62 - - 
DAS28 
 
-0.21 (-0.35;-0.07) <0.01 
maternal age 0.02 (0.01;0.04) <0.01 
prednisone - - 
    
Abbreviations: DAS28, disease activity score of rheumatoid arthritis in 28 joints with CRP levels - not 
included in the model because p>0.2; Adjusted for RA disease activity, maternal age, smoking, 
prednisone use and sulfazalazine use 
 
 
Table 2.3c - ANCOVA: Effect of dichotomised (high vs. low) cytokine levels in first trimester on birth 
weight SDS. Levels were put in the model simultaneously. 
First trimester   
 Crude (n=134) Adjusted (n=131) 
 ß (95% CI) p-value ß (95% CI) p-value 
IL-10 0.795 (0.10; 1.49) <0.03 0.819 (0.12; 1.52) 0.02 
     
IL-6 -0.542 (-0.91; -0.18) <0.01 -0.575 (-0.94; -0.21) <0.01 
maternal age   0.006 (-0.00; 0.01) 0.13  
     
Adjusted for RA disease activity, maternal age, smoking, prednisone use, sulfazalazine use 
 
 
Single-Nucleotide Polymorphisms  
Genotypes across all eight SNPs had no effect on the maternal cytokine levels even after 
correction for disease activity or medication use. Two SNPs were in Hardy-Weinberg 
disequilibrium and two had linkage disequilibrium (Table 2.4). Mothers who were 
homozygous for A in the polymorphism rs1800896 had new-borns with a significantly 
(p= 0.021) higher birth weight SDS, 0.27 (SD ± 1.02) compared with mothers 
homozygous for G, -0.34 (SD ± 1.03). Mean birth weight SDS in the heterozygous group 
was -0.14 (SD ± 1.11). 
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Table 2.3a - Effect of dichotomised (high vs. low) cytokine levels (crude-adjusted) on birth weight SDS 
First trimester (n=139) 
 Crude Adjusted 
 ß (95% CI) p-value ß (95% CI) p-value 
IL-10 0.62 (-0.08;1.32) 0.08 0.75 (0.04;1.46) 0.04 
DAS28 
 
-0.13 (-0.29;0.03) 0.11 
maternal age 0.02 (-0.01;0.04) 0.10 
prednisone -0.28 (-0.68; 0.12) 0.17 
     
IL-6 -0.47 (-0.83;-0.11) 0.01 -0.50 (-0.87;-0.13) <0.01 
DAS28  - - 
maternal age 0.01 (-0.00;0.01) 0.10 
     
TNFα  0.04 (-0.34;0.41) 0.85 - - 
DAS28 
 
- - 
maternal age - - 
prednisone -0.24 (-0.56;0.08) 0.15 
    
Abbreviations: DAS28, disease activity score of rheumatoid arthritis in 28 joints with CRP levels - not
included in the model because p>0.2; Adjusted for RA disease activity, maternal age, smoking,
prednisone use and sulfasalazine use 
 
 
During the first trimester, IL-6 was detectable in 71% of the patients with RA (n=95). It 
was high in 48% (n=67). The mean birth weight SDS was −0.26 in the high-IL-6 group 
and 0.21 in the low-IL-6 group. The high-IL-6 group was associated with lower birth 
weight SDS (difference −0.50, p=0.009) after adjustment for confounders (Table 2.3a). 
No such effect was seen at the other time points (Table 2.3b). When the effects of IL-6 
and IL-10 were analysed simultaneously, the effect was even more pronounced, 
resulting in a birth weight SDS increase of 0.82 for high IL-10 and a decrease of 0.58 for 
high IL-6 (Table 2.3c). 
   High levels of TNFα had no effect on birth weight SDS at any time point (Table 2.3a/b). 
Cytokine levels did not influence the gestational age (data not shown). In the reference 
group, cytokine levels were low and often undetectable (Table 2.1). Numbers were too 
small to allow statistical analysis 
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Table 2.3b - Effect of dichotomised (high vs. low) cytokine levels (crude-adjusted) on birth weight SDS 
Third trimester (n=161) 
 Crude Adjusted 
 ß (95% CI) p-value ß (95% CI) p-value 
IL-10 -0.21 (-0.94;0.53) 0.58 - - 
DAS28 
 
-0.21 (-0.35;-0.07) <0.01 
maternal age 0.02 (0.01;0.04) <0.01 
prednisone - - 
     
IL-6 -0.23 (-0.57;0.11) 0.19 - - 
DAS28  -0.22 (-0.35;0.08) <0.01 
maternal age 0.02 (0.01;0.37) <0.01 
     
TNFα  0.09 (-0.26;0.43) 0.62 - - 
DAS28 
 
-0.21 (-0.35;-0.07) <0.01 
maternal age 0.02 (0.01;0.04) <0.01 
prednisone - - 
    
Abbreviations: DAS28, disease activity score of rheumatoid arthritis in 28 joints with CRP levels - not 
included in the model because p>0.2; Adjusted for RA disease activity, maternal age, smoking, 
prednisone use and sulfazalazine use 
 
 
Table 2.3c - ANCOVA: Effect of dichotomised (high vs. low) cytokine levels in first trimester on birth 
weight SDS. Levels were put in the model simultaneously. 
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IL-6 -0.542 (-0.91; -0.18) <0.01 -0.575 (-0.94; -0.21) <0.01 
maternal age   0.006 (-0.00; 0.01) 0.13  
     
Adjusted for RA disease activity, maternal age, smoking, prednisone use, sulfazalazine use 
 
 
Single-Nucleotide Polymorphisms  
Genotypes across all eight SNPs had no effect on the maternal cytokine levels even after 
correction for disease activity or medication use. Two SNPs were in Hardy-Weinberg 
disequilibrium and two had linkage disequilibrium (Table 2.4). Mothers who were 
homozygous for A in the polymorphism rs1800896 had new-borns with a significantly 
(p= 0.021) higher birth weight SDS, 0.27 (SD ± 1.02) compared with mothers 
homozygous for G, -0.34 (SD ± 1.03). Mean birth weight SDS in the heterozygous group 
was -0.14 (SD ± 1.11). 
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Table 2.4 - Effect of genotype on cytokine levels and on birth weight SDS. 
SNP  MAF 
(n=134) 
MAF 
(n=120) 
HWE  Rank 
testc 
mean birth weight sds (n) Lineard 
 WT/var our pop HapMap p p Wt Hetero var p 
IL-10          
rs1800871a C/T 0.24 (T) 0.21 (T) 0.58 0.97 -0.23 (85) 0.08 (39) 0.12 (10) 0.13 
rs1800872a C/A 0.24 (A) 0.21 (A) 0.58 0.97 -0.23 (85) 0.08 (39) 0.12 (10) 0.13 
rs1800896 G/A 0.49 (A) 0.47 (A) 0.98 0.49 -0.34 (38) -0.14 (69) 0.27 (27) 0.03 
          
IL-6          
rs1800795b G/C 0.40 (C) 0.47 (G) 0.002 0.53 0.16 (34) 0.07 (50) -0.26 (50) 0.58 
rs1800797b G/A 0.38 (A) 0.48 (G) 0.01 0.64 -0.16 (30) 0.08 (51) -0.27 (53) 0.47 
          
TNFα           
rs2844482 e,f G/A 0.18 (A) 0.16 (A) 0.52 0.39 0.00 (87) -0.26 (44) -1.19 (2) 0.08 
rs1800629 G/A 0.20 (A) 0.22 (A) 0.56 0.42 -0.08 (87) -0.13 (40) -0.39 (7) 0.55 
rs1799724 C/T 0.08 (T) 0.10 (T) 1.00 0.56 -0.09(110) -0.25 (23) 0.74 (1) 0.78 
          
Abbreviations: SNP; Single-Nucleotide Polymorphism, WT; wild type, var; variant allele; MAF, Minor Allele
Frequency; HWE, Hardy-Weinberg equilibrium; Hetero, Heterozygote: a,b SNPs are in linkage
disequilibrium (r²≥ 0.8); c probability of the equality-of-populations using the Kruskal-Wallis rank test (chi-
squared with ties); d Linear regression, based on allele dose, dependent variable: birth weight SDS,
independent variable; genotype groups; e To evaluate the TNFα -863 (rs1800630) the tagged SNP ID
rs2844482 was taken; f could not be determined in all patients 
 
 
DISCUSSION 
 
We hypothesised that high maternal serum cytokine levels influence fetal growth in 
pregnant women with RA. This hypothesis appears to be true. In our prospective study, 
we observed that both IL-10 and IL-6 levels influence fetal growth in pregnant women 
with RA. During the first trimester, high IL-10 levels are associated with higher birth 
weight SDS, and high IL-6 levels are associated with lower birth weight SDS. This 
association was still present after correction for disease activity, maternal age, smoking, 
and use of prednisone and/or sulfasalazine during pregnancy. Unlike most studies, our 
study focused not only on the last trimester of the pregnancy, but also preconception 
and the first trimester, emphasising the importance of cytokine levels at the beginning 
of pregnancy. 
   Birth weight SDS was 0.75 higher in the high IL-10 group than in the low-IL-10 group. 
Birth weight SDS was 0.50 lower in the high IL-6 group than the low-IL-6 group. The 
effect of high levels became even more prominent when IL-10 and IL-6 levels were 
analysed simultaneously. Birth weight SDS was 0.82 higher in the high-IL-10 group and 
0.58 lower in the high-IL-6 group. A difference of 0.5 SDS is considered to be of clinical 

relevance, and therefore our findings are of relevance in women with high IL-10 and 
high IL-6 at the beginning of their pregnancy. 
   In our study, cytokine levels were independent of their functional SNPs. We explored 
the possibility of predicting birth weight based on preconception cytokine levels or 
functional variations in the relevant cytokine genes. However, no relation was found. 
These gene factors therefore describe insufficient variance to be useful in prediction. In 
addition, we observed that only the IL10 gene polymorphism, rs1800896—which in 
other studies is related to higher IL-10 levels14 22, was associated with birth weight, but it 
cannot be excluded that this is attributed to multiple testing. 
   To evaluate the effects of high cytokine levels, we studied an RA population that is 
often characterised by high serum cytokine levels. In our RA population, 16% had a 
detectable IL-10 level comparable with literature values28. Even though the literature 
indicates that different diseases may be associated with specific cytokine profiles during 
pregnancy29, the results of this study still may produce a better understanding of the 
consequences of high cytokine levels during pregnancy in general, but particularly in 
the first trimester. 
   A comparison group of 32 healthy pregnant women were included in the study. The 
main purpose of this reference group was to observe maternal serum cytokine levels in 
normal pregnancies. The number is too small to draw conclusions. 
   This study highlights the influence of cytokines throughout the first trimester of 
pregnancy, during which placentation occurs. The role of interleukins has not yet been 
fully clarified, but we hypothesise that cytokines influence placentation in various ways, 
by directly influencing placental growth factor (PlGF) and vascular endothelial growth 
factor (VEGF) and by indirectly influencing extracellular matrix (ECM) degradation. 
During normal placentation, cytotrophoblasts from the fetal stem cells differentiate and 
invade the uterine wall by destroying and displacing the ECM, which anchors the 
placenta to the uterus and provides maternal blood to the fetus. The presence and 
function of PlGF and VEGF are critical during placentation30. Anti-inflammatory 
cytokines such as IL-10 are considered to have a PlGF-enhancing effect31. Pro-
inflammatory cytokines such as TNFα and IL-6 have adverse effects on cytotrophoblast 
growth and development31. 
   One of the main mediators of ECM degradations is metalloproteinase-9 (MMP-9)32. 
Overexpression of MMP-9 is suggested to contribute to ECM degradation in the fetal 
membrane and placenta, thereby reducing placental function and even causing fetal 
membrane rupture or placental detachment33. Previous research has shown that IL-10 
inhibits the expression of MMP-9 in cytotrophoblasts34. Other studies have shown 
elevated levels of MMP-9 in pregnant women with RA35 In our population, maternal IL-
10 levels were more often detectable because of their RA. High IL-10 levels positively 
influence fetal growth, and therefore our data may support the idea that IL-10 
participates in the regulation of trophoblasts during human pregnancy by inhibiting 
MMP-9, thereby creating a more vital placenta. It also supports the idea that the MMP-9 
content in first-trimester trophoblasts is more important than in third- trimester cells.34. 
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Table 2.4 - Effect of genotype on cytokine levels and on birth weight SDS. 
SNP  MAF 
(n=134) 
MAF 
(n=120) 
HWE  Rank 
testc 
mean birth weight sds (n) Lineard 
 WT/var our pop HapMap p p Wt Hetero var p 
IL-10          
rs1800871a C/T 0.24 (T) 0.21 (T) 0.58 0.97 -0.23 (85) 0.08 (39) 0.12 (10) 0.13 
rs1800872a C/A 0.24 (A) 0.21 (A) 0.58 0.97 -0.23 (85) 0.08 (39) 0.12 (10) 0.13 
rs1800896 G/A 0.49 (A) 0.47 (A) 0.98 0.49 -0.34 (38) -0.14 (69) 0.27 (27) 0.03 
          
IL-6          
rs1800795b G/C 0.40 (C) 0.47 (G) 0.002 0.53 0.16 (34) 0.07 (50) -0.26 (50) 0.58 
rs1800797b G/A 0.38 (A) 0.48 (G) 0.01 0.64 -0.16 (30) 0.08 (51) -0.27 (53) 0.47 
          
TNFα           
rs2844482 e,f G/A 0.18 (A) 0.16 (A) 0.52 0.39 0.00 (87) -0.26 (44) -1.19 (2) 0.08 
rs1800629 G/A 0.20 (A) 0.22 (A) 0.56 0.42 -0.08 (87) -0.13 (40) -0.39 (7) 0.55 
rs1799724 C/T 0.08 (T) 0.10 (T) 1.00 0.56 -0.09(110) -0.25 (23) 0.74 (1) 0.78 
          
Abbreviations: SNP; Single-Nucleotide Polymorphism, WT; wild type, var; variant allele; MAF, Minor Allele
Frequency; HWE, Hardy-Weinberg equilibrium; Hetero, Heterozygote: a,b SNPs are in linkage
disequilibrium (r²≥ 0.8); c probability of the equality-of-populations using the Kruskal-Wallis rank test (chi-
squared with ties); d Linear regression, based on allele dose, dependent variable: birth weight SDS,
independent variable; genotype groups; e To evaluate the TNFα -863 (rs1800630) the tagged SNP ID
rs2844482 was taken; f could not be determined in all patients 
 
 
DISCUSSION 
 
We hypothesised that high maternal serum cytokine levels influence fetal growth in 
pregnant women with RA. This hypothesis appears to be true. In our prospective study, 
we observed that both IL-10 and IL-6 levels influence fetal growth in pregnant women 
with RA. During the first trimester, high IL-10 levels are associated with higher birth 
weight SDS, and high IL-6 levels are associated with lower birth weight SDS. This 
association was still present after correction for disease activity, maternal age, smoking, 
and use of prednisone and/or sulfasalazine during pregnancy. Unlike most studies, our 
study focused not only on the last trimester of the pregnancy, but also preconception 
and the first trimester, emphasising the importance of cytokine levels at the beginning 
of pregnancy. 
   Birth weight SDS was 0.75 higher in the high IL-10 group than in the low-IL-10 group. 
Birth weight SDS was 0.50 lower in the high IL-6 group than the low-IL-6 group. The 
effect of high levels became even more prominent when IL-10 and IL-6 levels were 
analysed simultaneously. Birth weight SDS was 0.82 higher in the high-IL-10 group and 
0.58 lower in the high-IL-6 group. A difference of 0.5 SDS is considered to be of clinical 
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relevance, and therefore our findings are of relevance in women with high IL-10 and 
high IL-6 at the beginning of their pregnancy. 
   In our study, cytokine levels were independent of their functional SNPs. We explored 
the possibility of predicting birth weight based on preconception cytokine levels or 
functional variations in the relevant cytokine genes. However, no relation was found. 
These gene factors therefore describe insufficient variance to be useful in prediction. In 
addition, we observed that only the IL10 gene polymorphism, rs1800896—which in 
other studies is related to higher IL-10 levels14 22, was associated with birth weight, but it 
cannot be excluded that this is attributed to multiple testing. 
   To evaluate the effects of high cytokine levels, we studied an RA population that is 
often characterised by high serum cytokine levels. In our RA population, 16% had a 
detectable IL-10 level comparable with literature values28. Even though the literature 
indicates that different diseases may be associated with specific cytokine profiles during 
pregnancy29, the results of this study still may produce a better understanding of the 
consequences of high cytokine levels during pregnancy in general, but particularly in 
the first trimester. 
   A comparison group of 32 healthy pregnant women were included in the study. The 
main purpose of this reference group was to observe maternal serum cytokine levels in 
normal pregnancies. The number is too small to draw conclusions. 
   This study highlights the influence of cytokines throughout the first trimester of 
pregnancy, during which placentation occurs. The role of interleukins has not yet been 
fully clarified, but we hypothesise that cytokines influence placentation in various ways, 
by directly influencing placental growth factor (PlGF) and vascular endothelial growth 
factor (VEGF) and by indirectly influencing extracellular matrix (ECM) degradation. 
During normal placentation, cytotrophoblasts from the fetal stem cells differentiate and 
invade the uterine wall by destroying and displacing the ECM, which anchors the 
placenta to the uterus and provides maternal blood to the fetus. The presence and 
function of PlGF and VEGF are critical during placentation30. Anti-inflammatory 
cytokines such as IL-10 are considered to have a PlGF-enhancing effect31. Pro-
inflammatory cytokines such as TNFα and IL-6 have adverse effects on cytotrophoblast 
growth and development31. 
   One of the main mediators of ECM degradations is metalloproteinase-9 (MMP-9)32. 
Overexpression of MMP-9 is suggested to contribute to ECM degradation in the fetal 
membrane and placenta, thereby reducing placental function and even causing fetal 
membrane rupture or placental detachment33. Previous research has shown that IL-10 
inhibits the expression of MMP-9 in cytotrophoblasts34. Other studies have shown 
elevated levels of MMP-9 in pregnant women with RA35 In our population, maternal IL-
10 levels were more often detectable because of their RA. High IL-10 levels positively 
influence fetal growth, and therefore our data may support the idea that IL-10 
participates in the regulation of trophoblasts during human pregnancy by inhibiting 
MMP-9, thereby creating a more vital placenta. It also supports the idea that the MMP-9 
content in first-trimester trophoblasts is more important than in third- trimester cells.34. 
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High RA disease activity is associated with lower birth weight6. There is a theory that 
high IL-10 levels are responsible for the improvement in RA during pregnancy28. One 
could speculate that the effect of IL-10 levels on birth weight is not related to their 
effect on placentation, but acts indirectly by reducing maternal disease activity during 
pregnancy. However, in our cohort, high IL-10 levels were not associated with an 
improvement in RA during pregnancy; patients with high IL-10 had higher DAS28 
during both in the first and third trimester than those with low IL-10. 
   Our main findings on IL-10 levels are consistent with mice studies. IL10 knockout mice 
were found to have more adverse pregnancy outcomes36. Fetal loss and fetal growth 
restriction have been shown to be attenuated by the administration of IL-10 to mice 
with endotoxin-induced IUGR10. These workers also showed that serum concentrations 
of TNFα and IL-6 were considerably higher in IL10 knockout mice than in the wild- type. 
This suggests that IL-10 modulates resistance to inflammatory stimuli by down 
regulating expression of pro-inflammatory cytokines such as TNFα and IL-6, protecting 
against inflammation-induced pathology37. 
   Finally, our study has some limitations. First, the biological effects of cytokines are 
determined by the interplay of cytokines and their soluble receptors. The levels of these 
soluble receptors were not determined. Second, it is known that body mass index may 
influence cytokine levels as well as pregnancy outcome and therefore it could be a 
potential confounder38. The body mass index of the participants was not recorded in 
this study. 
   In conclusion, our study shows that high levels of maternal IL-10 and IL-6 influence the 
birth weight of babies born to pregnant women with RA. The effect of high IL-10 and IL-
6 levels is most prominent in the first trimester when placentation occurs. As high IL-10 
and IL-6 levels influence birth weight, they may influence the future development of the 
child. 
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ABSTRACT  
 
 
Background  
Prednisone treatment and rheumatoid arthritis (RA) disease activity are both associated 
with a decrease in bone mineral density (BMD) of the patients. Both prednisone use and 
high disease activity may be inevitable in pregnant women with RA, but it is unknown if 
these variables influence the BMD of their offspring.  
 
Objectives 
To investigate whether medication or disease activity during pregnancy in patients with 
RA, influence the BMD of their prepubertal offspring. 
 
Methods 
Mothers (n=255) participated in a prospective cohort study on RA and pregnancy. Their 
children, age 5-10 years, were included in the follow-up study (n=108). The BMD of the 
children was assessed by Dual-Energy X-ray Absorptiometry. The following variables of 
the child were taken into account because they are known to influence the BMD, 
calcium intake, physical activity, serum 25-hydroxyvitamin D concentration, gender, 
length and weight. Pre- and postnatal variables known to influence the BMD are 
gestational age, maternal smoking, birth weight, postnatal tempo of growth and type of 
feeding. The independent variables were prednisone, sulfasalazine and RA disease 
activity during pregnancy. 
 
Results  
No association was found between prednisone use or RA disease activity during 
pregnancy and BMD of 7-years-old offspring, even after correcting for all known 
associated variables. Sulfasalazine use had a positive effect on the whole body BMD 
(difference in SDS=0.53; p=0.005). 
 
Conclusions  
Neither medication use nor high RA disease activity during pregnancy is associated with 
a decreased BMD of the 7-year-old offspring. The maternal benefit of RA medication 
during pregnancy outweighs the effect on the bone mineral density in the offspring. 
  


INTRODUCTION  
 
Medication use and the disease activity of rheumatoid arthritis (RA) may vary during 
pregnancy. Medication use during pregnancy is mainly restricted to prednisone, 
sulfasalazine and sometimes hydroxychloroquine. Prednisone is notorious for 
depressing the bone mineral density (BMD) of the patient. Nevertheless, in a male RA 
population sulfasalazine has been correlated with higher BMD1. Treatment is essential 
for pregnant women with RA, because decline of disease activity occurs in only half of 
women during pregnancy2. Elevated disease activity is also involved in the 
development of low BMD of the RA patient3,4. While it is known that medication and RA 
disease activity influence the BMD of the patient, it is unknown if they also influences 
the BMD of the offspring when present in pregnancy. 
   In general, many variables have been reported to influence the BMD during 
childhood. These variables can be divided into two groups, child-related variables and 
pre- and postnatal variables. Child-related variables are calcium intake, physical activity, 
serum 25-hydroxyvitamin D (25-OHD) concentration, gender, length, weight and body 
mass index (BMI)5,6. Pre- and postnatal variables that influence the BMD of the child are 
maternal smoking during pregnancy, gestational age, birth weight, mode of feeding in 
early postnatal life and tempo of growth in the first years of life7,8. Insufficient maternal 
serum 25-OHD levels has been associated with a lower BMD of the offspring, but this 
finding could not be confirmed in a large study on pregnancy outcome of healthy 
women9. It is unknown if pre- and postnatal variables associated with RA, like 
medication use or disease activity influence the BMD of the children. 
   The aim of the study was to determine, whether in addition to the already known 
factors, maternal medication use or RA disease activity during pregnancy are negatively 
associated with the BMD of their prepubertal offspring. 
 
 
PATIENTS AND METHODS 
 
Study Population 
Our study cohort consisted of healthy children born to mothers participating in the 
PARA-study (Pregnancy-induced Amelioration of Rheumatoid Arthritis), a prospective, 
nationwide cohort study on women with RA2. In the PARA-study, women with RA were 
visited by a research nurse at their home address at preconception, 3 times during 
pregnancy and 3 times postpartum. During these visits, blood was collected, 
information on medication recorded and RA disease activity (DAS28) calculated by 
examining 28 joints using 2 variables for each joint: number of swollen joints, number of 
tender joints, and measuring serum C-reactive protein (CRP) level10,11. Medical records 
were used to confirm gestational age. Birth weight was expressed as birth weight 
standard deviation scores (SDS), correcting for gestational age and gender2 12. 
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After participating in the PARA-study, the parents of all children (n=255) that were born 
in the PARA-study were contacted by mail. When the children were at least 5 years of 
age they were invited to visit the Sophia Children’s Hospital, Erasmus MC, Rotterdam. 
During this visit a questionnaire was completed by the parents e.g. to determine food 
intake and physical activity of the child. Blood samples were drawn from the children, 
anthropometric measurements were performed and the BMD (in grams/cm2) was 
measured by a DXA-scan (Dual-Energy X-ray Absorptiometry scan, type Lunar-Prodigy; 
GE Healthcare, Chalfont St. Giles, UK). All scans were made with the same machine, and 
quality assurance was performed daily. The coefficient of variation was 0.5% for total 
body BMD (BMDTB) and 1.0% for lumbar spine BMD (BMDLS)13-15. To adjust for differences 
in bone size, a BMAD (Bone Mineral Adjusted Density; grams/cm2) was assed. The 
BMADLS was calculated by the model BMDLS/ [4/(π / width)]16, with the width as the 
mean width of the second to fourth lumbar vertebral body. All the BMD values were 
transformed into SDS for sex and chronological age, according to Dutch reference 
values17,18. 
   Mothers and children were considered to be vitamin D insufficient when their serum 
25-OHD concentration was below 50 nmol/L9. The serum 25-OHD concentrations of the 
children at prepubertal age (5-10 year) were determined. Maternal levels were 
determined during early pregnancy. We used a 25-OHD 125I Radio Immuno Assay kit by 
DiaSorin, Stillwater, Minnesota 55082-0285, USA. The intra- and inter-assay coefficients 
of variation for samples were less than 11.7% and 9.4%. Our study was approved by the 
Medical Ethics Committee, Erasmus MC (Rotterdam). All parents gave their written 
informed consent. 
 
Statistical analysis 
Descriptive statistics are presented as numbers, percentages and means (SD). One-
sample t test was used to compare BMD SDS results with zero (mean value for age and 
sex matched references). Differences between the study population and the non-
participating group were investigated with t-tests for continuous variables measured 
and with χ2 tests for categorical variables. 
   First (step 1), univariate analyses were executed between BMDTBSDS or BMDLSSDS and 
all associated variables known to influence the BMD of the child. This included child-
related variables, like calcium intake of the child, physical activity, insufficient 25-OHD, 
gender, length, weight and BMI and variables related to the pre- and postnatal period, 
like maternal smoking during pregnancy, maternal insufficient 25-OHD, gestational age, 
birth weight, breast feeding after 12 weeks and tempo of growth in the first years of life 
Univariate analyses were also executed between BMDTBSDS or BMDLSSDS and the RA 
associated variable during pregnancy; maternal prednisone or sulfasalazine use and RA 
disease activity 
   Secondly (step 2), multivariate regression models were designed for BMDTBSDS and for 
BMDLSSDS to assess the effect of the RA associated variables during pregnancy. In this 


multivariate regression model, all associated variables in the univariate analysis (step 1) 
with a p-value<0.2 were used. To test for multicollinearity between the dependent 
variables, a variance inflation factor (VIF) was calculated19. Variables with a VIF>5 were 
excluded from the model. Once the model was produced the RA associated variables 
were imputed separately.  
   Finally (step 3), a multivariate regression model was fitted using backward selection 
starting with all known associated variables (step 1) and RA associated variables (step 2) 
with a p-value less than 0.2. Variables with the highest p-value were eliminated from the 
model until all p-values were less than 0.2. All statistical analyses were performed using 
STATA software (version 12.0 for Mac; StataCorp LP, Texas, USA). Statistical significance 
was defined as p< 0.05. 
 
RESULTS 
 
Fifty-five percent (108/196) of the eligible children participated in the study, including 3 
twins (Figure 1). Of the 45% (88/196) that did not participate in the study, 15% (13/88) 
were lost-to-follow-up and 85% (75/88) were unwilling to participate. The main reasons 
for non-participation was traveling to the hospital (38%) and the fact that parents felt 
that our investigations were too much of a burden for their child (30%). No significant 
differences were found for all variables between the study group (n=108) and the non-
participating group (n=88) (Supplementary Table; S4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 - Flowchart of the population studied 
 
   In the study group, the mean age of the children was 6.90 years (1.24) and the mean 
BMI SDS was -0.18 (0.88). The mean BMDTBSDS was -0.11 (0.10), which was comparable 
to zero and therefore equal to healthy controls. The mean BMDLSSDS was -0.20 (0.99) 
(not comparable to zero; p=0.04), but within the normal range. The mean BMDLS 
adjusted for differences in bone size, the mean BMADLSSDS was -0.05 (1.03) (comparable 
to zero) (Table 4.1). 
Born alive in the PARA study  
n = 255 
Excluded for present analyses   (n = 59) 
 Less than 5 years old  n = 57 
Diabets Mellitus type I of child n = 1 
 Breast cancer during pregnancy n = 1 
Eligible for present analyses 
n = 196 
Data available for analyses 
n = 108 
Data not available for present analyses  (n = 88) 
  Unwilling to Participate   n = 75 
Lost to follow up    n = 13 
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multivariate regression model, all associated variables in the univariate analysis (step 1) 
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that our investigations were too much of a burden for their child (30%). No significant 
differences were found for all variables between the study group (n=108) and the non-
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Figure 4.1 - Flowchart of the population studied 
 
   In the study group, the mean age of the children was 6.90 years (1.24) and the mean 
BMI SDS was -0.18 (0.88). The mean BMDTBSDS was -0.11 (0.10), which was comparable 
to zero and therefore equal to healthy controls. The mean BMDLSSDS was -0.20 (0.99) 
(not comparable to zero; p=0.04), but within the normal range. The mean BMDLS 
adjusted for differences in bone size, the mean BMADLSSDS was -0.05 (1.03) (comparable 
to zero) (Table 4.1). 
Born alive in the PARA study  
n = 255 
Excluded for present analyses   (n = 59) 
 Less than 5 years old  n = 57 
Diabets Mellitus type I of child n = 1 
 Breast cancer during pregnancy n = 1 
Eligible for present analyses 
n = 196 
Data available for analyses 
n = 108 
Data not available for present analyses  (n = 88) 
  Unwilling to Participate   n = 75 
Lost to follow up    n = 13 
Chapter 4
60


 
Table 4.1 - Characteristics of Mother and Child   
 Mean (SD)  
Clinical Characteristics Mother (n=105)   
   age at delivery (years) 32.5 (3.81)  
   RA duration at delivery (years) 7.49 (6.33)  
   insufficient 25-OHD (< 50 nmol/L) 22 (20)  
   
DAS28CRP    
   first trimester 
   third trimester 
3.65 (1.19) 
3.33 (1.18) 
 
   
Use of Medication during pregnancy   
   no medication 43 (41)  
   only Prednisone 27 (26)  
   only Sulfasalazine 17 (16)  
   only Hydroxychloroquine 1 (1)  
   combination Prednisone Sulfasalazine 16 (15)  
   combination Sulfasalazine 1 (1)  
   
Clinical Characteristics Child (n=108)   
At Birth   
   gender (M/F) 60/48  
   birth weight (kilograms) 3.37 (0.8)  
   gestational age (weeks) 39.4 (1.8)  
   birth weight SDS 0.03 (1.13)  
   birth length SDS 0.36 (1.24)  
   target Height SDS 0.88 (0.86)  
   
At 7-years-old   
   age (years) 6.90 (1.24)  
   weight SDS 0.07 (1.70)  
   height SDS 0.05 (0.98)  
   BMI SDS -0.18 (0.88)  
   BMDTB SDS -0.11 (0.10)  
   BMDLS SDS -0.20 (0.99)  
   BMADLS SDS -0.05 (1.03)  
   milk intake (servings/d) 1.7 (0.83)  
   physical activity (hrs/wk) 2.44 (1.79)  
   insufficient 25-OHD (< 50 nmol/L) 21 (20)  
   
All data are expressed as mean (SD) or number (%). Abbreviations: RA, rheumatoid arthritis; DAS28CRP, 
RA Disease Activity Score in 28 joints with CRP levels; SDS, Standard Deviation Score; BMD, Bone 
Mineral Density; TB, total body; LS, lumbar spine; BMAD, bone mineral adjusted density; 25-OHD, 25-
hydroxyvitamin D  
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Child-related variables 
The mean calcium intake of the child, expressed in daily milk intake, was 1.7 
servings/day (0.83), the mean physical activity was 2.4 hours/week (1.8). Five children 
refused to give blood. A total of 20% (21/103) had insufficient serum 25-OHD 
concentration (lower than 50 nmol/L) (Table 4.1). In the univariate analyses, these 
variables had no significant effect on the BMD of the child. 
   All anthropometric measurements of the child, like weight, height and BMI were 
associated with the BMDTBSDS and BMDLS SDS (Table 4.2). 
 
Pre- and postnatal variables 
Mean gestational age was 39.4 weeks and less than 5% (5/105) of the mothers smoked 
during pregnancy. Both variables had no association with the BMD of the child at 7-
years of age. Serum 25-OHD concentration was insufficient in 20% (22/108) of the 
mothers without any association on the BMD of the offspring. Mean birth weight SDS 
was 0.03 (1.8) and birth weight SDS was associated with BMDTBSDS (β=0.23, p=0.006) 
(Table 4.2) and BMDLSSDS (β=0.22, p=0.009) (Table 4.2).  
   Thirty-four percent of the mother’s breast-fed their child for more than 12 weeks. 
There was no significant association between the duration of breastfeeding and the 
BMD. Tempo of growth in weight for length in the first year of life had no effect on the 
BMD at 7 years (Table 4.2). 
 
RA-related variables  
Medication was used during pregnancy in 58% (63/108) of the mothers and restricted to 
prednisone (26%), sulfasalazine (16%), hydroxychloroquine (1%), a combination of 
prednisone and sulfasalazine (15%) or a combination of hydroxychloroquine and 
sulfasalazine (1%) (Table 4.1).  
   The median dose of prednisone was 6.2 mg/day with an interquartile range (IQR) of 1-
15mg/day. The median (IQR) dose of sulfasalazine was 2000 (500-4000) mg/day.  
   There was no significant association between prednisone use during pregnancy and 
the BMD of the offspring (Table 4.2). Sulfasalazine use had a positive effect on the 
BMDTBSDS of the child at 7 years (β= 0.50; p= 0.008), but had no effect on BMDLSSDS 
(Table 4.3). There was no dose-effect present for prednisone or sulfasalazine use  on the 
outcome (data not shown). 
   The RA disease activity (DAS28) decreased from 3.65 (SD 1.19) in the first to 3.33 (SD 
1.18) in the third trimester. DAS28 during pregnancy had no effect on the BMD of the 
child (Table 4.2). 
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1.18) in the third trimester. DAS28 during pregnancy had no effect on the BMD of the 
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Table 4.2 - Univariate analyses- Effect of the variables on the BMDTB and BMDLS (step 1) 
       BMDTBSDS         BMDLSSDS 
 β p-value β p-value 
Child-related variables     
   Calcium intake (servings/day) 0.17 0.14 0.13 0.27 
   Physical activity (hours/week) 0.04 0.46 -0.07 0.22 
   Insufficient 25-OHD (child)* -0.08 0.74 -0.04 0.88 
   Gender (m/f)* 0.03 0.88 -0.26 0.18 
   Weight (kg) 0.04 <0.01† 0.05   <0.01† 
   Height (cm) 0.03 <0.01 0.03 <0.01 
   BMI (sds) 0.26 0.02 0.38 <0.01 
 
Pre- and postnatal variables 
   Maternal smoking (y/n)* -0.03 0.59 -0.01 0.90 
   Insufficient 25-OHD (mother)* -0.33 0.17 -0.23 0.34 
   Gestational age (wks) 0.02 0.70 0.06 0.27 
   Birth weight (sds) 0.23 <0.01 0.22 <0.01 
   Breastfeeding (y/n)* -0.25 0.13 -0.02 0.88 
   Tempo height 0.03 0.74 0.04 0.71 
   Tempo weight -0.04 0.46 0.02 0.78 
     
RA-related variables     
   Prednisone* 0.28 0.15 -0.10 0.61 
   Sulfasalazine* 0.55 <0.01 0.33 0.11 
   DAS28- Trimester 1 0.02 0.83 -0.05 0.52 
   DAS28- Trimester 3 -0.02 0.76 -.010 0.25 
     
*variable analysed categorical; †variable was excluded from analysis VIF>10; Abbreviations: SDS, 
Standard Deviation Score; BMD, Bone Mineral Density; TB, total body; LS, lumbar spine; BMI, body mass 
index; Insufficient 25-OHD, 25-hydroxyvitamin D; DAS28, RA disease activity score in 28 joints with CRP 
levels. All bold variables were used for multivariate analyses for the BMD mentioned (step2) 
 
 
Multivariate regression model 
For the multivariate model with BMDTBSDS as dependent variable, the following 
variables were included based on their p-value (p<0.2) in the univariate analysis (step1); 
calcium intake, height of the child, BMI, birth weight SDS, mode of feeding and 
insufficient maternal 25-OHD level. Weight of the child was excluded from analysis due 
to a VIF of 33.17. When the RA variables were imputed separately (step 2), only maternal 
sulfasalazine had a p-value less than 0.2 and was therefore used in the final BMDTB 
model (step 3). This final model showed a significant association between BMDTBSDS 
and the height of the child (β=0.02; p=0.043) and sulfasalazine use (β = 0.53; p=0.005) 
(Table 4.4). This indicates that an increase in height of 10 cm or maternal sulfasalazine 
use results in a higher BMDTB of 0.2 or 0.5 SDS, respectively. 
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Table 4.3 - Multi-variate analyses-Effect of RA-related variables on the BMDTB and BMDLS (step 2) 
       BMDTBSDS a        BMDLSSDS b 
 β p-value β p-value 
RA-related variables     
   Prednisone* 0.24  0.20 0.01 0.96 
   Sulfasalazine* 0.50 <0.01 0.29  0.12 
   DAS28- Trimester 1 0.03 0.72 -0.03 0.73 
   DAS28- Trimester 3 0.01 0.89 -0.03 0.68 
     
*variable analysed categorical; a all adjusted for calcium intake; height, body mass index birth weight, 
breast feeding and 25-OHD (mother); b all adjusted for gender, height, BMI and birth weight; 
Abbreviations: SDS, Standard Deviation Score; BMD, Bone Mineral Density; TB, total body; LS, lumbar 
spine; DAS28, RA Disease Activity Score in 28 joints with CRP levels. 
 
 
 
For the multivariate BMDLSSDS model, the following variables were included based on 
the univariate analysis; gender of the child, height, BMI, birth weight SDS. Weight of the 
child was excluded from analysis due to a VIF of 32.4. When the RA variables were 
entered, only sulfasalazine was used in the final BMDLSmodel. This final model showed a 
significant association between BMDLSSDS and height (β=0.03; p=0.013) and BMI SDS of 
the child (β=0.25; p=0.026) (Table 4.4). In the final BMDLSSDS model, the association with 
maternal sulfasalazine was not significant. 
 
 
 
Table 4.4 - Multivariate analyses-Association on BMDTB and BMDLS using backward selection (step 3) 
       BMDTBSDS     BMDLSSDS  
Variables β p-value β p-value 
Sulfasalazine* 0.53 <0.01 0.29 0.13 
Calcium 0.19 0.07   
Gender (m/f)*   - - 
Height (cm) 0.02 0.04 0.03 0.01 
BMI (sds) - - 0.25 0.03 
Birth weight (sds) 0.14 0.10 - - 
Breastfeeding (y/n)* -0.28 0.07   
Insufficient 25-OHD -0.29 0.18   
     
*variable analysed categorical; Abbreviations: SDS, Standard Deviation Score; BMD, Bone Mineral 
Density; TB, total body; LS, lumbar spine; BMI, body mass index; 25-OHD, 25-hydroxyvitamin D; -, variable 
not included in model (limit for inclusion p<0.2). 
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DISCUSSION 
 
Our study indicated that prednisone use or elevated RA disease activity during 
pregnancy in women with RA had no influence on the total body or lumbar spine bone 
density of their 7-year-old offspring. Furthermore, sulfasalazine had no negative 
influence on the bone mineral density and even showed a positive association of 0.5 
SDS with the total body bone density of the child. Our hypothesis that maternal 
medication or RA disease activity during pregnancy could be negatively associated with 
the current BMD of the 7-year-old offspring is therefore refuted. 
   Prednisone creates bone loss by affecting the precursors of osteoblasts and 
osteoclasts and by lowering serum calcium and vitamin D levels through decreasing 
intestinal absorption of calcium3,20. Prednisone does not pass the placenta, but the 
placenta is not yet fully developed at 12 weeks of pregnancy, so in this stage the fetus 
may be exposed. During this early period of embryonic development the skeleton 
begins as a cartilaginous scaffold, followed by the primary ossification between 8th and 
12th weeks. Most of the bone mineralization is completed during the third trimester of 
pregnancy21. In previous studies we already showed that prednisone shortens the 
gestational age, but no influence was found on the pre- or postnatal growth of the child  
(see also Chapter 3)22. With current findings, we cannot rule out that maternal 
prednisone use might influence this prenatal process of embryonic development. We 
do conclude that maternal prednisone use has no effect on the BMD of the 7-year old 
offspring. 
   It has been reported that sulfasalazine use correlates with higher BMD, however it was 
unknown whether maternal sulfasalazine use during gestation influences the BMD of 
the offspring1. Sulfasalazine passes the placenta and is present in breast milk. The ratio 
of maternal to cord plasma (or breast milk) for most sulfasalazine metabolites is 
approximately 1:1-1:223. Therefore, an infant may be exposed to sulfasalazine for a long 
pre- and postnatal period. A large nationwide study found no increase in congenital 
malformations when pregnant women were using sulfasalazine24. It is in line with 
literature that sulfasalazine has a positive influence on BMD, but until now it was 
unknown that maternal use has also an effect on the BMD of the 7-year-old offspring. 
   In this study the focus of the BMD measurement was on two different bone sites, total 
body (BMDTB) and lumbar spine (BMDLS). Total body is mainly composed of cortical bone 
and when mechanical stress is increased, cortical bone increases in size, but not in 
density. Any effect during pre- and postnatal period will probably be on the cortical 
bone and not the trabecular bone. This is comparable to our results because pre- and 
postnatal variables, including sulfasalazine use during pregnancy, seem to affect the 
BMDTB more than the BMDLS. Lumbar spine is composed of trabecular bone and this will 
increase in density when mechanical stress like weight and physical activity is 
enhanced25,26. Our results also support this hypothesis based on the stronger association 
found between height, weight and BMI with BMDLS than BMDTB outcomes 5,6. 


   Our previous study did show that elevated RA disease during pregnancy is associated 
with a lower birth weight and with rapid catch-up in weight for length during the first 
year of life 2,27. Both have been related to an unfavorable cardiovascular and metabolic 
profile in adults. We therefore want to emphasize that elevated RA disease activity 
should be avoided during pregnancy highlighting the important role for medication 
like prednisone and sulfasalazine in reaching this goal. 
   Finally, our study had some limitations as only 55% of all eligible children participated 
in the study. Although there was no statistical difference between the participating and 
non-participating group, there could be a bias due to missing data.. 
   In conclusion, our study shows that neither medication nor elevated RA disease 
activity during pregnancy is associated with a lower whole body or lumbar spine BMD 
in 7-year-old offspring. The aim of the study was reached because our study shows that 
maternal medication use has no effect on the bone density of the 7-year old offspring. 
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literature that sulfasalazine has a positive influence on BMD, but until now it was 
unknown that maternal use has also an effect on the BMD of the 7-year-old offspring. 
   In this study the focus of the BMD measurement was on two different bone sites, total 
body (BMDTB) and lumbar spine (BMDLS). Total body is mainly composed of cortical bone 
and when mechanical stress is increased, cortical bone increases in size, but not in 
density. Any effect during pre- and postnatal period will probably be on the cortical 
bone and not the trabecular bone. This is comparable to our results because pre- and 
postnatal variables, including sulfasalazine use during pregnancy, seem to affect the 
BMDTB more than the BMDLS. Lumbar spine is composed of trabecular bone and this will 
increase in density when mechanical stress like weight and physical activity is 
enhanced25,26. Our results also support this hypothesis based on the stronger association 
found between height, weight and BMI with BMDLS than BMDTB outcomes 5,6. 


   Our previous study did show that elevated RA disease during pregnancy is associated 
with a lower birth weight and with rapid catch-up in weight for length during the first 
year of life 2,27. Both have been related to an unfavorable cardiovascular and metabolic 
profile in adults. We therefore want to emphasize that elevated RA disease activity 
should be avoided during pregnancy highlighting the important role for medication 
like prednisone and sulfasalazine in reaching this goal. 
   Finally, our study had some limitations as only 55% of all eligible children participated 
in the study. Although there was no statistical difference between the participating and 
non-participating group, there could be a bias due to missing data.. 
   In conclusion, our study shows that neither medication nor elevated RA disease 
activity during pregnancy is associated with a lower whole body or lumbar spine BMD 
in 7-year-old offspring. The aim of the study was reached because our study shows that 
maternal medication use has no effect on the bone density of the 7-year old offspring. 
 
   
Chapter 4
66


  
Supplementary Table S4 - Characteristics of the population studied and those lost-to-follow-up 
 study population 
(n=105) 
lost-to-follow-up  
(n=88)* 
 
 mean (SD) mean (SD) p-value 
Clinical Characteristics Mother    
age at delivery (years) 32.6 (3.81) 32.3 (3.55)a 0.63 
RA duration at delivery (years) 7.49 (6.33)b 6.29 (6.08)c 0.19 
    
Disease activity during pregnancy    
   first trimester 
   third trimester  
3.65 (1.19)d 
3.33 (1.18) 
3.70 (1.03)e 
3.35(1.04)f 
0.77 
0.88 
    
Use of Medication during pregnancy n (%) n (%) p-value 
   no medication 
   prednisone  
   only Sulfasalazine  
44 (42) 
26 (25) 
17 (16) 
41 (48)g 
24 (28)g 
14(16)g 
0.33 
   combination of two 18 (17) 7 (8)g  
    
Clinical Characteristics Child  (n=108) (n=88) p-value 
birth weight (kilograms) 3.422 3.255a 0.06 
gestational age (weeks) 39.5 39.1a 0.22 
birth weight SDS 0.05 -0.20a 0.11 
gender (M/F) 57/48 51/34a 0.43 
    
Mode of feeding 12 weeks post-partum  % % p-value 
   only breast  
   only formula 
   both 
34 (36/105) 
61 (64/105) 
5 (5/105) 
40 (34/85) 
53 (45/85) 
7 (6/85) 
0.50 
    
All data are expressed as mean (SD) or percentage * lost-to-follow-up (n=13) + unwilling to participate 
(n=75) (see also figure 1; flowchart); a n =85; b n =104;  c n=84; d n= 89; e n=71; f n=82; g n=86. 
Abbreviations: RA, rheumatoid arthritis; DAS28, RA Disease Activity Score in 28 joints with CRP levels; 
SDS, Standard Deviation Score 

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In this thesis, we describe findings in a large group of children aged 5-10 years. The 
mothers of these children were all diagnosed with rheumatoid arthritis (RA) and were 
prospectively followed during and after their pregnancy. This thesis presents RA 
associated variables during pregnancy, mainly RA disease activity and RA medication, 
and the associations with determinants of adult health and diseases in the offspring. 
Determinants of adult health being present at an early age include body composition, 
lipids, blood pressure, cortisol levels and insulin resistance. These determinants 
influence the risk on diseases in adulthood, like cardiovascular diseases (CVD) or type 2 
diabetes mellitus (T2DM)1-4.  
   In the present chapter each paragraph covers a different period in early life. Beginning 
with the fetal period (I), followed by the postnatal period during the first year (II), and 
finally the prepubertal period from 5-10 years (III) (Figure 8.1). The main findings 
concerning the determinants of adult health are described in the beginning of each 
paragraph and discussed at the end of the paragraph. Recent literature and clinical 
implications will be discussed where possible. At the end of this chapter, an overall 
interpretation of the results and direction for future research are given. Finally, a 
recommendation for treatment of pregnant women with RA will be specified.  
 
 
 
 
Figure 8.1 - Associations found between RA variables during pregnancy, and early risk factors of 
diseases in adulthood. These risk factors can be present during fetal period (I), first year of life (II), 
or at prepubertal age (III). 
 
 
FETAL PERIOD (I) 
 
Circulating cytokines 
The fetal period is one of, if not the most, critical phase in life of every human being. 
Many factors can influence the fetal growth of the child, like maternal malnutrition, 
smoking, alcohol abuse, maternal weight, gestational weight gain and maternal 
hypertension5-8. Birth weight is a proxy for the fetal growth and function of the placenta. 
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Birth weight was transformed into a birth weight standard deviation score (birth weight 
SDS), which corrects the birth weight for gestational age and gender9.  
   Elevated RA disease activity during pregnancy has been shown to negatively influence 
the birth weight SDS of the child10. The mechanism of how a systemic disease, like RA, in 
which mainly synovial tissues are targeted, affects the growth of the fetus is unknown. 
Due to the fact that elevated RA disease activity is often accompanied by elevated 
cytokines, we hypothesized that circulating cytokines affect fetal growth. By assessing 
two pro-inflammatory cytokines, TNFα and IL-6 and one anti-inflammatory cytokine, IL-
10, we wanted to explain how elevated RA disease activity during pregnancy is 
associated with low birth weight SDS of the child10.  
   Based on animal studies we postulated that elevated pro-inflammatory cytokines in 
pregnant women with RA will negatively influence the fetal growth, and elevated anti-
inflammatory cytokines will positively influence the fetal growth11,12.  
   Maternal cytokine levels were measured at pre-conception and during the first and 
third trimesters. We also genotyped certain functional Single-Nucleotide 
Polymorphisms (SNPs), which are known to influence the concentration levels of IL-10, 
IL-6 and TNFα. The genotyping of these functional SNPs was executed to explore the 
possibility to predict birth weight based on pre-conception cytokine levels or functional 
variations in the relevant cytokine genes. 
   We observed that in pregnant women with RA, IL-10 and IL-6 levels influence the fetal 
growth of the child. During the first trimester, high anti-inflammatory IL-10 levels are 
associated with higher birth weight SDS, and high pro-inflammatory IL-6 levels are 
associated with lower birth weight SDS13. This association remained present after 
correction for RA disease activity, maternal age, smoking, prednisone or sulfasalazine 
use during pregnancy. 
   Furthermore, the association was only present in the first trimester and not in the third 
or at preconception. High levels of pro-inflammatory TNFα had no effect on birth 
weight SDS. Furthermore, the circulating cytokines levels of IL-10, IL-6 and TNFα were 
not related with the corresponding SNPs.  
 
Discussion and clinical implication 
 
Our finding, that an elevated level of IL-10 is associated with higher birth weight SDS of 
the child is consistent with animal studies. IL-10 knockout mice showed more adverse 
pregnancy outcome than wild-type mice12. We also found that elevated IL-10 levels 
positively influenced birth weight independent of RA disease activity. This suggests a 
protective role for IL-10 during pregnancy concerning the fetal growth of the child and 
also supports the idea that IL-10 participates in the regulation of trophoblasts during 
human pregnancy, creating a more vital placenta14,15.  
   That elevated IL-6 levels were found in association with lower birth weight SDS is also 
in line with animal studies, which have highlighted that elevated pro-inflammatory 
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or at prepubertal age (III). 
 
 
FETAL PERIOD (I) 
 
Circulating cytokines 
The fetal period is one of, if not the most, critical phase in life of every human being. 
Many factors can influence the fetal growth of the child, like maternal malnutrition, 
smoking, alcohol abuse, maternal weight, gestational weight gain and maternal 
hypertension5-8. Birth weight is a proxy for the fetal growth and function of the placenta. 
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Birth weight was transformed into a birth weight standard deviation score (birth weight 
SDS), which corrects the birth weight for gestational age and gender9.  
   Elevated RA disease activity during pregnancy has been shown to negatively influence 
the birth weight SDS of the child10. The mechanism of how a systemic disease, like RA, in 
which mainly synovial tissues are targeted, affects the growth of the fetus is unknown. 
Due to the fact that elevated RA disease activity is often accompanied by elevated 
cytokines, we hypothesized that circulating cytokines affect fetal growth. By assessing 
two pro-inflammatory cytokines, TNFα and IL-6 and one anti-inflammatory cytokine, IL-
10, we wanted to explain how elevated RA disease activity during pregnancy is 
associated with low birth weight SDS of the child10.  
   Based on animal studies we postulated that elevated pro-inflammatory cytokines in 
pregnant women with RA will negatively influence the fetal growth, and elevated anti-
inflammatory cytokines will positively influence the fetal growth11,12.  
   Maternal cytokine levels were measured at pre-conception and during the first and 
third trimesters. We also genotyped certain functional Single-Nucleotide 
Polymorphisms (SNPs), which are known to influence the concentration levels of IL-10, 
IL-6 and TNFα. The genotyping of these functional SNPs was executed to explore the 
possibility to predict birth weight based on pre-conception cytokine levels or functional 
variations in the relevant cytokine genes. 
   We observed that in pregnant women with RA, IL-10 and IL-6 levels influence the fetal 
growth of the child. During the first trimester, high anti-inflammatory IL-10 levels are 
associated with higher birth weight SDS, and high pro-inflammatory IL-6 levels are 
associated with lower birth weight SDS13. This association remained present after 
correction for RA disease activity, maternal age, smoking, prednisone or sulfasalazine 
use during pregnancy. 
   Furthermore, the association was only present in the first trimester and not in the third 
or at preconception. High levels of pro-inflammatory TNFα had no effect on birth 
weight SDS. Furthermore, the circulating cytokines levels of IL-10, IL-6 and TNFα were 
not related with the corresponding SNPs.  
 
Discussion and clinical implication 
 
Our finding, that an elevated level of IL-10 is associated with higher birth weight SDS of 
the child is consistent with animal studies. IL-10 knockout mice showed more adverse 
pregnancy outcome than wild-type mice12. We also found that elevated IL-10 levels 
positively influenced birth weight independent of RA disease activity. This suggests a 
protective role for IL-10 during pregnancy concerning the fetal growth of the child and 
also supports the idea that IL-10 participates in the regulation of trophoblasts during 
human pregnancy, creating a more vital placenta14,15.  
   That elevated IL-6 levels were found in association with lower birth weight SDS is also 
in line with animal studies, which have highlighted that elevated pro-inflammatory 
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cytokines, such as IL-6 negatively influence the function and growth of the placenta11,13. 
Additionally, they can have adverse effects on the growth and development of 
cytotrophoblasts, which are crucial for placentation14. Our results partly support this 
conclusion, because the elevated IL-6 levels had a negative influence on birth weight 
and the association was only found in the first trimester of pregnancy, in which the 
placentation occurs. No association was found with TNFα. 
   Circulating cytokine levels at pre-conception or during the third trimester did not 
associate with birth weight SDS. One of the explanations could be that during the third 
trimester, the cytokine levels are not only determined by the RA disease activity, but 
also by other mechanisms. Nevertheless, it does highlight the importance of cytokines 
throughout the first trimester of pregnancy in which placentation occurs. 
   In our study, cytokine levels were not related with the functional SNPs. We explored 
the possibility to predict birth weight based on pre-conception cytokine levels or 
functional variations in the relevant cytokine genes, but no relation was found.  
   RA medication, such as prednisone and sulfasalazine may influence the level of 
circulating cytokines. Questions can be raised concerning new RA therapies, involving 
the use of biologicals, which are mainly, though not exclusively, therapeutic antibodies 
targeting pro-inflammatory cytokines, including TNFα and IL-616-18. Therapy with 
recombinant human IL-10 was not effective in suppressing RA disease activity in non-
pregnant RA patients19. Nevertheless, recombinant human IL-10 is very effective in 
suppressing Crohn's disease activity20. Biologicals targeting IL-6, like Tocilizumab, are 
not yet considered safe during pregnancy. Therefore, at this moment, it is clinically not 
possible to rebalance IL-10 and IL-6 levels in pregnant women. Perhaps anti-TNF 
medication can create a rebalance in circulating cytokines. TNF-blockers have been 
categorized as “group B” by the Food and Drug Administration (FDA), meaning that 
animal reproduction studies have failed to demonstrate a risk to the fetus, but no 
adequate and well-controlled studies in pregnant women have been done. This 
implicates that no firm conclusions can be drawn about the safety of anti-TNF therapy 
during pregnancy21. 
   Our findings indicate that rheumatologists should be aware that elevated cytokine 
levels could influence the birth weight SDS of the child, which is a proxy for the fetal 
growth. Nevertheless, measuring cytokines throughout the pregnancy or even before 
conception is not implicated. Adequate RA therapy remains crucial during pregnancy, 
not to diminish RA disease activity and to reduce pro-inflammatory cytokine levels. 
 
 
FIRST YEAR PERIOD (II) 
 
Tempo of postnatal growth  
Recent studies showed that rapid postnatal catch-up growth in weight for height is 
related to unfavorable cardiovascular and metabolic profiles later in life1,2. This 
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association is even stronger when the most prominent increase in weight occurs during 
the first three months of life, which is called rapid catch-up1. Accelerated weight gain 
during this specific period negatively affects health profile at 21 years1. 
   When a child is born with a lower birth weight, catch-up growth in weight and height 
may occur and the tempo of this catch-up is crucial. Elevated RA disease activity during 
pregnancy is associated with low birth weight SDS, but no association is present 
between RA medication and birth weight SDS10. We therefore hypothesized that 
children, who were exposed to elevated RA disease activity in utero, will experience 
more catch-up growth in weight, but no such effect will be present in children who 
were exposed to RA medication in utero. 
   In our study we found that with every point increase in RA disease activity (DAS28, 
range 0-10), the odds for rapid catch-up growth in weight increased with factor 1.44. 
This means that when a mother has high RA disease activity (DAS28 > 5.1) during 
pregnancy, the child has 7.5 times higher chance of a less favorable health profile in 
early adulthood than expected. 
   The growth in weight for height at the age of two years did not differ between the 
children with high or low disease activity during pregnancy. Although this might appear 
reassuring, it has been shown that rapid catch-up in weight in the first 3 months of life is 
often followed by a normal growth pattern during infancy, but nevertheless associated 
with a less favorable health profile in the future2. As hypothesized, children who were 
exposed to prednisone or sulfasalazine in utero had no different growth pattern during 
the first year than those who were not exposed. 
 
Discussion and clinical implication 
 
We concluded that elevated RA disease activity during pregnancy increased the risk of 
rapid catch-up in weight in the first year. This is an indication that active RA disease 
activity during pregnancy might be a risk factor for unfavorable cardiovascular and 
metabolic profile later in the lives of the offspring. Our study emphasizes the 
importance of having low RA disease activity, but more importantly our study showed 
that medication use, including prednisone, during pregnancy had no influence on the 
tempo of growth. Based on our findings, low maternal disease activity should be 
pursued during pregnancy. Not only is it beneficial for the pregnant women, it could 
also result in a healthier postnatal gain in weight in the infant.  
   Our data shows that clinicians should always consider combination therapy when 
treatment with only prednisone, sulfasalazine, or hydroxychloroquine is failing. More 
than half of the mothers in this study used medication during pregnancy, but only one 
fifth used a combination of medication. In other studies combination therapy is even 
lower22. Continuation, or extension of RA medication will not only improve the maternal 
health during pregnancy, but this study also shows that it could affect future health of 
the unborn child.  
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cytokines, such as IL-6 negatively influence the function and growth of the placenta11,13. 
Additionally, they can have adverse effects on the growth and development of 
cytotrophoblasts, which are crucial for placentation14. Our results partly support this 
conclusion, because the elevated IL-6 levels had a negative influence on birth weight 
and the association was only found in the first trimester of pregnancy, in which the 
placentation occurs. No association was found with TNFα. 
   Circulating cytokine levels at pre-conception or during the third trimester did not 
associate with birth weight SDS. One of the explanations could be that during the third 
trimester, the cytokine levels are not only determined by the RA disease activity, but 
also by other mechanisms. Nevertheless, it does highlight the importance of cytokines 
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   In our study, cytokine levels were not related with the functional SNPs. We explored 
the possibility to predict birth weight based on pre-conception cytokine levels or 
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   RA medication, such as prednisone and sulfasalazine may influence the level of 
circulating cytokines. Questions can be raised concerning new RA therapies, involving 
the use of biologicals, which are mainly, though not exclusively, therapeutic antibodies 
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recombinant human IL-10 was not effective in suppressing RA disease activity in non-
pregnant RA patients19. Nevertheless, recombinant human IL-10 is very effective in 
suppressing Crohn's disease activity20. Biologicals targeting IL-6, like Tocilizumab, are 
not yet considered safe during pregnancy. Therefore, at this moment, it is clinically not 
possible to rebalance IL-10 and IL-6 levels in pregnant women. Perhaps anti-TNF 
medication can create a rebalance in circulating cytokines. TNF-blockers have been 
categorized as “group B” by the Food and Drug Administration (FDA), meaning that 
animal reproduction studies have failed to demonstrate a risk to the fetus, but no 
adequate and well-controlled studies in pregnant women have been done. This 
implicates that no firm conclusions can be drawn about the safety of anti-TNF therapy 
during pregnancy21. 
   Our findings indicate that rheumatologists should be aware that elevated cytokine 
levels could influence the birth weight SDS of the child, which is a proxy for the fetal 
growth. Nevertheless, measuring cytokines throughout the pregnancy or even before 
conception is not implicated. Adequate RA therapy remains crucial during pregnancy, 
not to diminish RA disease activity and to reduce pro-inflammatory cytokine levels. 
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Tempo of postnatal growth  
Recent studies showed that rapid postnatal catch-up growth in weight for height is 
related to unfavorable cardiovascular and metabolic profiles later in life1,2. This 
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association is even stronger when the most prominent increase in weight occurs during 
the first three months of life, which is called rapid catch-up1. Accelerated weight gain 
during this specific period negatively affects health profile at 21 years1. 
   When a child is born with a lower birth weight, catch-up growth in weight and height 
may occur and the tempo of this catch-up is crucial. Elevated RA disease activity during 
pregnancy is associated with low birth weight SDS, but no association is present 
between RA medication and birth weight SDS10. We therefore hypothesized that 
children, who were exposed to elevated RA disease activity in utero, will experience 
more catch-up growth in weight, but no such effect will be present in children who 
were exposed to RA medication in utero. 
   In our study we found that with every point increase in RA disease activity (DAS28, 
range 0-10), the odds for rapid catch-up growth in weight increased with factor 1.44. 
This means that when a mother has high RA disease activity (DAS28 > 5.1) during 
pregnancy, the child has 7.5 times higher chance of a less favorable health profile in 
early adulthood than expected. 
   The growth in weight for height at the age of two years did not differ between the 
children with high or low disease activity during pregnancy. Although this might appear 
reassuring, it has been shown that rapid catch-up in weight in the first 3 months of life is 
often followed by a normal growth pattern during infancy, but nevertheless associated 
with a less favorable health profile in the future2. As hypothesized, children who were 
exposed to prednisone or sulfasalazine in utero had no different growth pattern during 
the first year than those who were not exposed. 
 
Discussion and clinical implication 
 
We concluded that elevated RA disease activity during pregnancy increased the risk of 
rapid catch-up in weight in the first year. This is an indication that active RA disease 
activity during pregnancy might be a risk factor for unfavorable cardiovascular and 
metabolic profile later in the lives of the offspring. Our study emphasizes the 
importance of having low RA disease activity, but more importantly our study showed 
that medication use, including prednisone, during pregnancy had no influence on the 
tempo of growth. Based on our findings, low maternal disease activity should be 
pursued during pregnancy. Not only is it beneficial for the pregnant women, it could 
also result in a healthier postnatal gain in weight in the infant.  
   Our data shows that clinicians should always consider combination therapy when 
treatment with only prednisone, sulfasalazine, or hydroxychloroquine is failing. More 
than half of the mothers in this study used medication during pregnancy, but only one 
fifth used a combination of medication. In other studies combination therapy is even 
lower22. Continuation, or extension of RA medication will not only improve the maternal 
health during pregnancy, but this study also shows that it could affect future health of 
the unborn child.  
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At such a young age of 5-10 years, the increased risk due to rapid catch-up might be 
reduced if the child creates a healthy lifestyle. Creating a healthy lifestyle by education 
and counselling is always important, but perhaps even more important in children with 
an increased risk due to rapid catch-up in weight. 
   It is vital that for a child born with a low birth weight SDS, due to the elevated RA 
disease or any other reason, that the tempo of weight gain is kept moderate, especially 
during the first 3 months. Adequate monitoring of the weight and height in the post-
natal period is crucial2. 
   While underlining the importance of our findings we do want to emphasize the 
relative magnitude of our results. Although we found significant associations between 
disease activity and the tempo of postnatal weight gain, the growth of the majority of 
the children was within the normal range. However, our findings may have greater 
consequences in other countries were RA disease activity is less well controlled. The 
overall DAS28 in The Netherlands is 3.1, while this is 4.4 in Non-European countries23. 
 
 
PREPUBERTAL PERIOD (III)  
 
Growing evidence suggests that ‘re-programming’ of the fetus occurs during early 
development in response to in utero variations in environment. This ‘re-programming’ 
may be involved in the presence of risk factors at young age, leading to diseases in 
adulthood24. Adverse in utero environment variations may be generated by RA disease 
activity or RA medication during pregnancy. This may then lead to fetal adaptions, 
which re-program the hormone secretion and metabolism of the fetus25. This fetal ‘re-
programming’ can be beneficial on the short term, but may increase the risk of several 
diseases later in life24,26. One example is maternal malnutrition, creating low intrauterine 
supply of nutrients, which could lead to fetal re-programming. Also prolonged fetal 
exposure to synthetic glucocorticoids is assumed to create an adverse effect on the fetal 
programming by re-setting the fetal hypothalamic-pituitary-adrenal (HPA) axis25-30. 
Animal studies showed a reduced, negative feedback of the HPA axis when exposed to 
synthetic glucocorticoids in utero. This re-setting of the fetal HPA axis led to elevated 
glucocorticoid levels and high blood pressure in the offspring at adult age31.  
   In the first two paragraphs we investigated the risk during the fetal period and the first 
year of life to develop a less favorable health profile in adulthood. Obviously, to be 
certain if children develop diseases in adulthood we have to wait a few more decades. 
We determined risk factors, which were already present at prepubertal age. We 
therefore determined the effect of maternal RA disease activity and medication use on 
the following parameters. 
 
 
 


Daytime cortisol levels 
Prednisone exposure in utero could have long-term consequences for the child, 
resulting in elevated cortisol levels or early signs of insulin resistance27-30. We found that 
children who were prednisone-exposed in utero had a slightly elevated daytime cortisol 
level compared to the non-exposed and compared to age-specific references32. This 
association was independent of age, gender and RA disease activity. We therefore 
concluded that prednisone-exposure in utero is associated with a higher overall daytime 
cortisol level at the prepubertal age. 
 
Metabolic syndrome  
To assess the risk of adult diseases, like cardiovascular disease (CVD), insulin resistance, 
or obesity at an early age, several determinants can be measured, like components of 
the metabolic syndrome (MetS). This is a combination of 5 closely related cardiovascular 
risk factors which have been adapted for the use in children: abdominal obesity, high 
triglyceride (TG), low high-density lipoproteine (HDL), high blood pressure and high 
fasting glucose3. When 3 or more components are present the child has MetS. No 
association was found between elevated RA disease activity or RA medication and 
increased prevalence of MetS. Also the five components of MetS were not increased 
when the children were exposed to elevated RA disease activity or prednisone in utero. 
 
Abdominal obesity  
The total amount and distribution of the fat mass can be assessed using skinfold 
thicknesses or DXA-scan (Dual-Energy X-ray Absorptiometry). A higher amount of total 
fat mass during childhood tends to track into adulthood, increasing the risk for obesity 
and insulin resistance33-35. Abdominal distribution of body fat is associated with insulin 
resistance and dyslipidemia33. In our study we found no differences in the total amount 
or distribution of body fat in the children who were exposed to elevated RA disease 
activity or prednisone in utero. 
 
Insulin resistance 
Insulin resistance can be a precursor of the MetS and T2DM and can be evaluated with 
the Homeostasis Model of Assessment Insulin Resistance (HOMA-IR) and adiponectin 
concentration insulin resistance 36-40. Neither elevated RA disease activity, nor RA 
medication were associated with the prevalence of insulin resistance or adiponectin 
level in the prepubertal offspring. 
 
Dyslipidemia 
High levels of triglycerides, cholesterol and low levels of high-density lipoprotein can all 
be early indicators for a unfavorable health profile later in life. We found no association 
between elevated RA disease activity or RA medication and an unfavorable lipid profile 
in the offspring. 
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Daytime cortisol levels 
Prednisone exposure in utero could have long-term consequences for the child, 
resulting in elevated cortisol levels or early signs of insulin resistance27-30. We found that 
children who were prednisone-exposed in utero had a slightly elevated daytime cortisol 
level compared to the non-exposed and compared to age-specific references32. This 
association was independent of age, gender and RA disease activity. We therefore 
concluded that prednisone-exposure in utero is associated with a higher overall daytime 
cortisol level at the prepubertal age. 
 
Metabolic syndrome  
To assess the risk of adult diseases, like cardiovascular disease (CVD), insulin resistance, 
or obesity at an early age, several determinants can be measured, like components of 
the metabolic syndrome (MetS). This is a combination of 5 closely related cardiovascular 
risk factors which have been adapted for the use in children: abdominal obesity, high 
triglyceride (TG), low high-density lipoproteine (HDL), high blood pressure and high 
fasting glucose3. When 3 or more components are present the child has MetS. No 
association was found between elevated RA disease activity or RA medication and 
increased prevalence of MetS. Also the five components of MetS were not increased 
when the children were exposed to elevated RA disease activity or prednisone in utero. 
 
Abdominal obesity  
The total amount and distribution of the fat mass can be assessed using skinfold 
thicknesses or DXA-scan (Dual-Energy X-ray Absorptiometry). A higher amount of total 
fat mass during childhood tends to track into adulthood, increasing the risk for obesity 
and insulin resistance33-35. Abdominal distribution of body fat is associated with insulin 
resistance and dyslipidemia33. In our study we found no differences in the total amount 
or distribution of body fat in the children who were exposed to elevated RA disease 
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Insulin resistance 
Insulin resistance can be a precursor of the MetS and T2DM and can be evaluated with 
the Homeostasis Model of Assessment Insulin Resistance (HOMA-IR) and adiponectin 
concentration insulin resistance 36-40. Neither elevated RA disease activity, nor RA 
medication were associated with the prevalence of insulin resistance or adiponectin 
level in the prepubertal offspring. 
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High levels of triglycerides, cholesterol and low levels of high-density lipoprotein can all 
be early indicators for a unfavorable health profile later in life. We found no association 
between elevated RA disease activity or RA medication and an unfavorable lipid profile 
in the offspring. 
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Bone mineral density 
Prednisone is notorious for depressing bone mineral density (BMD), but sulfasalazine 
has been correlated with higher BMD in a male RA population41. We found that RA 
medication does not negatively influence BMD of the offspring, 5-10 years after 
exposure in utero. Maternal prednisone use was not associated with lower BMD and 
sulfasalazine medication even showed a significantly higher BMD in the offspring. 
 
Discussion and clinical implication 
 
During the prepubertal period, we did not find an association between RA disease 
activity or RA medication and increased risk for diseases in adulthood. Nonetheless, 
follow-up studies need to be performed to assess whether these risk factors remain 
absent in the future. 
   Children who were prednisone-exposed in utero had a slightly elevated daytime 
cortisol level compared to the children who were not prednisone-exposed and 
compared to the mean cortisol levels of the age-specific references32. Cortisol levels 
were higher, but within the normal range. The cortisol elevation of the prednisone-
exposed children was not associated with higher BMI or blood pressure. The latter is 
reassuring, but does not exclude possible long-term consequences of persistently 
higher daytime cortisol levels. Our results warrant follow-up of our study population to 
evaluate the consequences of higher cortisol levels in adolescence. 
   The fact that both elevated RA disease activity and prednisone-exposure in utero did 
not negatively influence the health profile of the prepubertal offspring is reassuring for 
now and does not lead to any clinical implications considering medication use in 
pregnant women with RA. Nevertheless, it does create concern about the effects of 
prednisone-exposure in utero when higher synthetic glucocorticoids doses are given.  
 
 
GENERAL DISCUSSION  
 
At the end of this chapter, we discuss the strength and limitation of our study and the 
overall interpretation of the results concerning RA disease activity and RA treatment 
during pregnancy. Recommendations for clinicians concerning pregnant women with 
RA are given as well as recommendations for future research.  
 
Strength and limitations of our study population 
The main strength of this study is that all pregnancies were prospectively followed. 
Medication intake and RA disease activity was followed throughout the entire 
pregnancy and always assessed by the same research assistants. Furthermore, all data 
concerning the prepubertal children were measured and collected by one doctor to 
limit the variation in measurements. Only 55% of all eligible children participated in the 


study. Nevertheless, there was no statistical difference in independent variables 
between the participating (n=108) and non-participating group (n=88).  
   We conducted a nationwide study, but all children were examined at the Sophia 
Children’s Hospital in Rotterdam. The main reason for unwillingness to participate was 
the distance to the hospital (38%), or that parents felt that the investigations were too 
much of a burden for their child (30%). We contacted most of the parents and only 5% 
(13/255) were lost to follow-up.  
 
Overall interpretation concerning RA disease activity during pregnancy 
In this thesis, we showed that the adverse fetal environment, due to elevated RA disease 
activity, is associated with fetal growth retardation leading to low birth weight SDS13. 
We also showed the association between elevated RA disease activity and rapid catch-
up growth in weight in the first year of life. Both phenomena are associated with an 
increased risk for diseases in adulthood, like CVD and T2DM2. Nevertheless, at the age of 
5-10 years, there was no association between elevated RA disease activity and the 
presence the presence of MetS, abdominal obesity, insulin resistance or dyslipidemia. 
All might be risk factors of diseases in adult life. This can be explained in different ways. 
   At the age of 5-10 years, additional factors become more important in determining the 
presence of early risk factors for future disease, like weight, height and body mass index 
(BMI) of the child. In line with literature, we did find an association between birth weight 
SDS and height, weight, BMI and lean body mass at the age of 5-10 years1. If the cohort 
would have been larger we might have found an association between RA disease 
activity and these variables as well. 
   Another explanation for the fact that no association was found between elevated RA 
disease activity during pregnancy and early risk factors at 5-10 years could be that the 
association is only detectable later in life. During puberty, the child will physically 
change and the body and the body composition will fully develop. Literature shows 
that an early rapid catch-up in weight is often followed by a normal growth pattern 
during childhood, but is nevertheless associated with a less favorable health profile in 
the future2. 
   A third explanation could be the non-invasive methods that were chosen in this study 
to determine risk factors, because of the young age of the children. For example, the 
preferred method to quantify insulin resistance is hyperinsulinemic euglycemic clamp 
(HEC) or the intravenous glucose tolerance test (IGTT). We selected a less invasive and 
therefore more ethically approved approach. In that respect, it is of great importance 
that all children are seen in the future in a follow-up study until the children have 
reached adulthood and are preferably tested by HEC or IGTT. 
   Due to the fact that we found associations between elevated RA disease activity 
during pregnancy and some risk factors, we would advise to diminish the RA disease 
activity during pregnancy as much as possible (Figure 8.2). The association between 
elevated RA disease activity during pregnancy and low birth weight SDS, including 
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concerning the prepubertal children were measured and collected by one doctor to 
limit the variation in measurements. Only 55% of all eligible children participated in the 


study. Nevertheless, there was no statistical difference in independent variables 
between the participating (n=108) and non-participating group (n=88).  
   We conducted a nationwide study, but all children were examined at the Sophia 
Children’s Hospital in Rotterdam. The main reason for unwillingness to participate was 
the distance to the hospital (38%), or that parents felt that the investigations were too 
much of a burden for their child (30%). We contacted most of the parents and only 5% 
(13/255) were lost to follow-up.  
 
Overall interpretation concerning RA disease activity during pregnancy 
In this thesis, we showed that the adverse fetal environment, due to elevated RA disease 
activity, is associated with fetal growth retardation leading to low birth weight SDS13. 
We also showed the association between elevated RA disease activity and rapid catch-
up growth in weight in the first year of life. Both phenomena are associated with an 
increased risk for diseases in adulthood, like CVD and T2DM2. Nevertheless, at the age of 
5-10 years, there was no association between elevated RA disease activity and the 
presence the presence of MetS, abdominal obesity, insulin resistance or dyslipidemia. 
All might be risk factors of diseases in adult life. This can be explained in different ways. 
   At the age of 5-10 years, additional factors become more important in determining the 
presence of early risk factors for future disease, like weight, height and body mass index 
(BMI) of the child. In line with literature, we did find an association between birth weight 
SDS and height, weight, BMI and lean body mass at the age of 5-10 years1. If the cohort 
would have been larger we might have found an association between RA disease 
activity and these variables as well. 
   Another explanation for the fact that no association was found between elevated RA 
disease activity during pregnancy and early risk factors at 5-10 years could be that the 
association is only detectable later in life. During puberty, the child will physically 
change and the body and the body composition will fully develop. Literature shows 
that an early rapid catch-up in weight is often followed by a normal growth pattern 
during childhood, but is nevertheless associated with a less favorable health profile in 
the future2. 
   A third explanation could be the non-invasive methods that were chosen in this study 
to determine risk factors, because of the young age of the children. For example, the 
preferred method to quantify insulin resistance is hyperinsulinemic euglycemic clamp 
(HEC) or the intravenous glucose tolerance test (IGTT). We selected a less invasive and 
therefore more ethically approved approach. In that respect, it is of great importance 
that all children are seen in the future in a follow-up study until the children have 
reached adulthood and are preferably tested by HEC or IGTT. 
   Due to the fact that we found associations between elevated RA disease activity 
during pregnancy and some risk factors, we would advise to diminish the RA disease 
activity during pregnancy as much as possible (Figure 8.2). The association between 
elevated RA disease activity during pregnancy and low birth weight SDS, including 
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rapid catch-up growth in weight, may have such an impact on the future health of the 
child that elevated RA disease activity during pregnancy should be avoided. The child 
will benefit when born with a higher birth weight and less risk to experience rapid 
catch-up in weight for length in the first year of life. Furthermore, the mother will 
strongly benefit during pregnancy when the disease activity is lower, which will lead to 
less morbidity and disability and a better condition after delivery when she has to take 
care of her child. 
 
Overall interpretation concerning RA treatment during pregnancy 
The use of RA medication during pregnancy, and especially prednisone, will always be 
controversial. In this thesis we only found an association between prednisone use 
during pregnancy and a higher daytime cortisol level in the prepubertal offspring.
Those higher cortisol levels were, however, within the normal range and not 
accompanied by clinical outcomes, like higher BMI or blood pressure. The latter is 
reassuring, but does not exclude possible long-term consequences of persistently 
higher daytime cortisol levels. There were no other associations between prednisone 
use during pregnancy and the presence of early risk factors on adult disease at this 
young age, like the presence of MetS, abdominal obesity, insulin resistance or 
dyslipidemia. It has to be mentioned that the administrated prednisone dose was a 
relatively low dose of approximately 6.0 mg/day (range 1-15mg). 
   Some studies demonstrated that pregnant women with RA, who discontinued 
medication, had unfavorable outcomes in terms of preterm delivery, than women who 
continued their medications22. Late-preterm or early term infants have more medical 
complications than infants born between 39 and 40 weeks of gestation42. Furthermore, 
low RA disease activity during conception is relevant for a stable, low level of disease 
activity during pregnancy43,44. All these studies support medication use to achieve a 
healthier pregnancy outcome (Figure 8.2). 
 
 
 
 
 
Figure 8.2 – Recommendation for clinicians concerning pregnant women with RA 
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Besides continuation of RA medication we also recommend counseling and guidance of 
women with RA who have a pregnancy wish by a clinician (Figure 8.2). The association 
found between elevated RA disease activity during pregnancy and early risk factors on 
adult diseases is most prominent in early pregnancy. It is therefore crucial that at 
preconception, all potential perinatal risk factors, including RA disease activity and RA 
medication, are evaluated by a clinician and discussed with the patient. Change in 
medication, but also lifestyle interventions, prior to pregnancy could lead to improved 
pregnancy outcome45. However, as nearly 50% of pregnancies in the United States are 
unplanned, clinicians, most importantly rheumatologist, should be aware of safe 
alternatives concerning RA medication in women of childbearing age46. 
   None of the mothers in our study population used TNF-blockers, because TNF-blockers 
were a novelty at the time of this study and not yet prescribed during pregnancy. Only 
recently, TNF-blockers have been categorized as “group B” by the FDA and are therefore 
more frequently prescribed during pregnancy to control active RA. TNF-blockers pass 
the placenta and when given during pregnancy, inoculation of the offspring with live 
vaccines is contraindicated until the biologic agent is no longer detectable in the child's 
circulation47,48. A case of fatal disseminated mycobacterial infection has been reported in 
an infant of a mother who was receiving Infliximab for Crohn’s disease throughout her 
pregnancy47. Being born healthy and receiving BCG vaccine at 3 months, he died 1.5 
months later from disseminated BCG infection. 
   Still, there is no evidence that TNF-blockers are associated with embryotoxicity, 
teratogenicity or increased pregnancy loss, compared with pregnancies unexposed to 
biologics in RA or other diseases, like inflammatory bowel disease (IBD)49,50. In case of 
IBD, a recent systematic review found no association between administration of TNF-α 
inhibitors and adverse pregnancy outcome, congenital abnormalities, or increased 
relative risk of infections in the first year of life of the offspring49. Their advice was that 
biologics should be discontinued during pregnancy solely if the IBD is in remission 
using the same stop criteria as for patients with IBD in general, as uncontrolled activity 
of IBD may expose the mother and child to a risk greater than those only potentially 
coming from the use of TNF-α inhibitors49. 
   Based on literature, we would advise to use TNF-α inhibitors during pregnancy only 
when highly necessary, preferably only in the first trimester and always under the 
supervision of a rheumatologist or other physicians. Future studies concerning large 
registries of pregnant women using biologials will be necessary before firm conclusions 
can be drawn. 
 
Recommendations for future research 
Not all components of health in the offspring who were exposed to prednisone have 
been explored. This study did not address the mental and cognitive development of the 
prednisone-exposed children. Prednisone has been given for many decades and in 
some studies adverse effects have been described on fetal programming resulting in 
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rapid catch-up growth in weight, may have such an impact on the future health of the 
child that elevated RA disease activity during pregnancy should be avoided. The child 
will benefit when born with a higher birth weight and less risk to experience rapid 
catch-up in weight for length in the first year of life. Furthermore, the mother will 
strongly benefit during pregnancy when the disease activity is lower, which will lead to 
less morbidity and disability and a better condition after delivery when she has to take 
care of her child. 
 
Overall interpretation concerning RA treatment during pregnancy 
The use of RA medication during pregnancy, and especially prednisone, will always be 
controversial. In this thesis we only found an association between prednisone use 
during pregnancy and a higher daytime cortisol level in the prepubertal offspring.
Those higher cortisol levels were, however, within the normal range and not 
accompanied by clinical outcomes, like higher BMI or blood pressure. The latter is 
reassuring, but does not exclude possible long-term consequences of persistently 
higher daytime cortisol levels. There were no other associations between prednisone 
use during pregnancy and the presence of early risk factors on adult disease at this 
young age, like the presence of MetS, abdominal obesity, insulin resistance or 
dyslipidemia. It has to be mentioned that the administrated prednisone dose was a 
relatively low dose of approximately 6.0 mg/day (range 1-15mg). 
   Some studies demonstrated that pregnant women with RA, who discontinued 
medication, had unfavorable outcomes in terms of preterm delivery, than women who 
continued their medications22. Late-preterm or early term infants have more medical 
complications than infants born between 39 and 40 weeks of gestation42. Furthermore, 
low RA disease activity during conception is relevant for a stable, low level of disease 
activity during pregnancy43,44. All these studies support medication use to achieve a 
healthier pregnancy outcome (Figure 8.2). 
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Besides continuation of RA medication we also recommend counseling and guidance of 
women with RA who have a pregnancy wish by a clinician (Figure 8.2). The association 
found between elevated RA disease activity during pregnancy and early risk factors on 
adult diseases is most prominent in early pregnancy. It is therefore crucial that at 
preconception, all potential perinatal risk factors, including RA disease activity and RA 
medication, are evaluated by a clinician and discussed with the patient. Change in 
medication, but also lifestyle interventions, prior to pregnancy could lead to improved 
pregnancy outcome45. However, as nearly 50% of pregnancies in the United States are 
unplanned, clinicians, most importantly rheumatologist, should be aware of safe 
alternatives concerning RA medication in women of childbearing age46. 
   None of the mothers in our study population used TNF-blockers, because TNF-blockers 
were a novelty at the time of this study and not yet prescribed during pregnancy. Only 
recently, TNF-blockers have been categorized as “group B” by the FDA and are therefore 
more frequently prescribed during pregnancy to control active RA. TNF-blockers pass 
the placenta and when given during pregnancy, inoculation of the offspring with live 
vaccines is contraindicated until the biologic agent is no longer detectable in the child's 
circulation47,48. A case of fatal disseminated mycobacterial infection has been reported in 
an infant of a mother who was receiving Infliximab for Crohn’s disease throughout her 
pregnancy47. Being born healthy and receiving BCG vaccine at 3 months, he died 1.5 
months later from disseminated BCG infection. 
   Still, there is no evidence that TNF-blockers are associated with embryotoxicity, 
teratogenicity or increased pregnancy loss, compared with pregnancies unexposed to 
biologics in RA or other diseases, like inflammatory bowel disease (IBD)49,50. In case of 
IBD, a recent systematic review found no association between administration of TNF-α 
inhibitors and adverse pregnancy outcome, congenital abnormalities, or increased 
relative risk of infections in the first year of life of the offspring49. Their advice was that 
biologics should be discontinued during pregnancy solely if the IBD is in remission 
using the same stop criteria as for patients with IBD in general, as uncontrolled activity 
of IBD may expose the mother and child to a risk greater than those only potentially 
coming from the use of TNF-α inhibitors49. 
   Based on literature, we would advise to use TNF-α inhibitors during pregnancy only 
when highly necessary, preferably only in the first trimester and always under the 
supervision of a rheumatologist or other physicians. Future studies concerning large 
registries of pregnant women using biologials will be necessary before firm conclusions 
can be drawn. 
 
Recommendations for future research 
Not all components of health in the offspring who were exposed to prednisone have 
been explored. This study did not address the mental and cognitive development of the 
prednisone-exposed children. Prednisone has been given for many decades and in 
some studies adverse effects have been described on fetal programming resulting in 
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impairment of fetal growth27. Other studies showed less fetal brain development and 
neurologic consequences, some still present in the 6 to 10-years-old-offspring28-30. It is 
strongly recommended that the investigators evaluate the psychological development 
of the children, including reading or attention disorders, when the children of our 
current study population are seen in a follow-up study. The higher daytime cortisol level 
found in the in utero prednisone-exposed offspring also warrant continued follow-up to 
evaluate the long-term consequences of higher cortisol levels on the health profile in 
adolescence and adulthood. 
   In conclusion, the main findings of our study show that circulating IL-10 and IL-6 
influence the birth weight SDS in pregnant women with RA, elevated RA disease activity 
increases the risk of fast catch-up growth in weight during the first year, and prednisone 
use increases daytime cortisol levels at prepubertal age (Figure 8.3). More importantly 
this thesis highlights the fact that many early determinants for increased risk of diseases 
in adulthood are not present when RA medication is given. The main conclusion of this 
thesis might therefore be that elevated RA disease activity is more damaging to mother 
and child than the use of RA medication. Physician should strive to avoid high RA 
disease activity during pregnancy. Continuation, or extension of RA medication will not 
only improve the maternal health during and after pregnancy, but it may also affect 
future health of the unborn child. 
 
 
 
 
Figure 8.3 – The main associations found in this thesis between maternal RA determinants 
during pregnancy and early determinants of adult diseases in the offspring. 
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impairment of fetal growth27. Other studies showed less fetal brain development and 
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this thesis highlights the fact that many early determinants for increased risk of diseases 
in adulthood are not present when RA medication is given. The main conclusion of this 
thesis might therefore be that elevated RA disease activity is more damaging to mother 
and child than the use of RA medication. Physician should strive to avoid high RA 
disease activity during pregnancy. Continuation, or extension of RA medication will not 
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This doctoral dissertation describes the results found in the FEPRA-study (FEtal 
Programming in Rheumatoid Arthritis). In this study, detailed description is given on RA 
associated variables during pregnancy, namely prednisone use and RA disease activity, 
and the consequences of these variables on the offspring. 
 
 
Chapter 1  
 
This chapter gives an overview of definitions, prevalence and medical treatment of 
rheumatoid arthritis (RA). It provides a general introduction on RA during pregnancy 
and birth outcome. Furthermore, it describes different hypotheses with regard to the 
influence of birth size and childhood growth on adult diseases and their determinants. 
The main aim of the study was to assess if RA determinants, like RA disease activity, 
medication use and the presence of RA autoantibodies, are associated with the 
prevalence of early life determinants of adult diseases in the offspring. These early life 
determinants are described during 3 different periods in early life: the fetal period (I) in 
Chapter 2, the postnatal period during the first year (II) in Chapter 3 and the period 
before puberty (III) in Chapter 4-7. 
 
 
 
 
Figure 9.1 - Associations found between RA variables during pregnancy, and early risk factors for 
diseases in adulthood. These risk factors can be present during fetal period (I), first year of life (II), 
or at prepubertal age (III). 
 
 
Chapter 2  
 
This chapter defines the association between elevated serum cytokine levels in the 
pregnant women with RA and the birth weight of the child. Birth weight is expressed in 
birth weight standard deviation scores (birth weight SDS), corrected for gestational age 
and gender. A difference of 0.5 SDS is considered to be of clinical relevance. 
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   During first trimester, maternal serum levels of interleukin-10 (IL-10) and interleukin-6 
(IL-6) were associated with fetal growth, independent of the RA disease activity. In the 
high IL-10 group the birth weight SDS was 0.75 higher compared to the low IL-10 
group. In the group of women with high IL-6 the birth weight SDS was 0.50 lower 
compared to the low IL-6 group.  
   When analysed simultaneously the effect was even more pronounced, resulting in a 
birth weight SDS increase of 0.82 for high IL-10 and a decrease of 0.58 for high IL-6. No 
such correlation was seen with tumor necrosis factor-alpha (TNFα) or in third trimester 
of pregnancy. 
 
 
Chapter 3  
 
Previous studies in children born to healthy mothers have shown that rapid catch-up in 
weight during the first 3 months after birth is related to unfavorable cardiovascular and 
metabolic profiles later in life. To investigate the effect of RA during pregnancy on the 
future development of the child we analyzed the tempo of this postnatal weight.  
   We found that elevated RA disease activity during pregnancy is associated with rapid 
catch-up in weight independent of medication or the presence of RA associated 
antibodies. Therefore, elevated RA disease activity should be avoided during pregnancy 
because it could be a risk factor for unfavorable cardiovascular and metabolic profile 
later in life.  
   Medication during pregnancy, including prednisone, had no effect on growth. From 
this it can be concluded that continuation or extension of medication aimed at 
acquiring low maternal disease activity during pregnancy, will not only improve 
maternal health during pregnancy, but may also affect the future health of the unborn 
child. 
 
 
Chapter 4 
 
In this chapter the associations between RA medication and RA disease activity of the 
mother during pregnancy and the bone mineral density (BMD) of the child is described. 
Prednisone is notorious for depressing the BMD of the patient, but sulfasalazine has 
been correlated with higher BMD in a male RA population.  
   We concluded that neither medication use nor high RA disease activity during 
pregnancy is associated with a decreased BMD of the 7-year-old offspring. The maternal 
benefit of RA medication during pregnancy outweighs the effect on the bone mineral 
density in the offspring. 
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Chapter 5  
 
To investigate whether prednisone or elevated RA disease activity in pregnant women 
with RA were associated with the presence of early determinants for cardiovascular 
diseases (CVD) or type 2 diabetes mellitus (T2DM) we assessed the body composition of 
the child and the components of the metabolic syndrome (MetS) adjusted for children.  
   MetS is a combination of 5 closely related cardiovascular risk factors: abdominal 
obesity, high triglyceride (TG), low high-density lipoproteïne (HDL), high blood pressure 
and high fasting glucose.  
   The body composition of the child was assessed by anthropometric measurement and 
by a dual-energy X-ray absorptiometry-scan (DXA), showing the total amount and 
distribution of lean body mass and fat mass 
   Our study shows that children born from mother with RA have no elevated risk on 
early determinants for CVD and T2DM based on the presence of MetS. Furthermore, we 
concluded that prednisone and RA disease activity in pregnant women with RA had no 
influence on the body composition of their 7-years-old offspring. 
 
 
Chapter 6  
 
In this chapter we focused on whether prednisone use in pregnant women with RA is 
associated with an increased prevalence of insulin resistance of their prepubertal 
offspring. The difference in insulin resistance between the exposed and the non-
exposed was based on the fat distribution of the child, fasting blood samples including 
the Homeostasis Model of Assessment Insulin Resistance (HOMA-IR) and adiponectin 
levels. HOMA-IR is a method used to quantify insulin resistance using fasting levels of 
glucose and insulin. Healthy children have a HOMA-IR of 1. 
   We concluded that children who were exposed to prednisone in utero had no increase 
in insulin resistance compared to the non-exposed children. Furthermore, the 
prednisone-exposed children had similar fat distribution and similar adiponectin levels.  
 
 
Chapter 7 
 
To assess whether fetal prednisone exposure influences the HPA axis activity of the 
offspring (5-10 years )multiple salivary cortisol samples were taken during the day: at 
awakening, 30 minutes after awakening, afternoon, bedtime. Children who were 
exposed to prednisone in utero had higher daytime cortisol levels compared to the non-
exposed children. The difference was small and not associated with a higher body mass 
index or blood pressure of the children. Therefore, these findings will not lead to 
revision of therapeutic treatment of pregnant women with RA who need prednisone. 


Still, it does create concern about prednisone exposure in utero, especially when higher 
doses of prednisone are given than in current study. Our results warrant further studies 
concerning higher doses of prednisone use during pregnancy and the long-term effects 
in the offspring. 
 
 
Chapter 8 
 
The general discussion is dedicated to the main findings of the FEPRA-study described 
in this thesis. Conclusions are explained in the light of current literature and clinical 
implications of the results are given including recommendations for future research.  
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In dit proefschrift worden de resultaten weergegeven die gevonden zijn in de FEPRA-
studie (FEtal Programming in Rheumatoid Arthritis-studie). Het doel van de studie was 
te onderzoeken of er een associatie is tussen de ziekteactiviteit van reumatoïde artritis 
(RA) inclusief medicatiegebruik tijdens de zwangerschap en de aanwezigheid van 
vroege risicofactoren op toekomstige ziektes in het nageslacht (5-10 jaar). 
 
 
Hoofdstuk 1  
 
Dit hoofdstuk geeft een overzicht van de definitie, prevalentie en behandeling van 
reumatoïde artritis (RA). Het geeft een algemene introductie van RA tijdens de 
zwangerschap en de invloed van RA op het ongeboren kind. Verder worden hypotheses 
besproken waarin verschillende voorspellende factoren op toekomstige ziektes worden 
uitgelegd. Deze voorspellende factoren kunnen zijn een laag geboortegewicht, de 
snelheid waarin een kind groeit in het eerste jaar, en de opeenstapeling van vet in het 
lichaam. Deze voorspellende factoren zijn tijdens verschillende periodes in het leven 
aanwezig, daarom worden er 3 verschillende periodes in het vroege leven van het kind 
beschreven: de foetale periode (I) in hoofdstuk 2, de postnatale periode (II) in 
hoofdstuk 3 en de periode voor de puberteit, (III) in hoofdstuk 4-7. 
 
 
 
 
Figuur 10.1 –Associaties onderzocht in dit proefschrift tussen RA tijdens de zwangerschap en de 
reeds bekende risicofactoren op toekomstige ziektes Deze risicofactoren kunnen aanwezig zijn 
tijdens de foetale periode (I), het eerste levensjaar (II) of vlak voor de puberteit (III). 
 
 
Hoofdstuk 2  
 
Dit hoofdstuk beschrijft de associatie tussen verhoogde serumconcentraties van 
cytokines in de zwangere vrouwen met RA en het geboortegewicht van het kind. 
Geboortegewicht is uitgedrukt in geboortegewicht standaard deviatie score (SDS). Dit 
betekent dat het gewicht van het kind is gecorrigeerd voor de duur van de 
ziekte op volwassen leeftijd 
	

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zwangerschap en het geslacht van het kind. In de kliniek wordt een verschil van 0.5 SDS 
beschouwd als relevant.  
   De studie laat zien dat een verhoogde serumconcentratie van interleukine-10 (IL-10) 
en van interleukine-6 (IL-6) tijdens het eerste trimester van de zwangerschap 
geassocieerd zijn met geboortegewicht van het kind. De gevonden associatie was 
onafhankelijk van de ziekteactiviteit van de RA. In de groep met hoog IL-10 was het 
geboortegewicht SDS 0.75 hoger in vergelijking tot de groep met laag IL-10. In de 
groep met hoog IL-6 was het geboortegewicht SDS 0.50 lager in vergelijk tot de groep 
met laag IL-6. Wanneer beide cytokines tegelijkertijd in een model werden 
geanalyseerd was het effect op het geboortewicht zelfs groter. Zo’n gecombineerd 
model resulteerde in een toename van het geboortegewicht SDS met 0.82 in de groep 
met hoog IL-10 en een afname van het geboortegewicht SDS met 0.58 voor de groep 
met hoog IL-6. Er werd geen relatie gevonden tussen de serumconcentratie van tumor-
necrosis factor-alpha (TNFα) en het geboortegewicht.  
 
 
Hoofdstuk 3  
 
Eerdere studies naar kinderen van gezonde vrouwen hebben laten zien dat een snelle 
inhaalgroei in gewicht tijdens de eerste drie maanden na de bevalling kan leiden tot 
cardiovasculaire en metabole aandoeningen op volwassen leeftijd. Om het effect van 
RA tijdens de zwangerschap op de toekomstige ontwikkeling van het kind te analyseren 
hebben we de inhaalgroei in de eerste drie levensmaanden onderzocht  
   We vonden dat een verhoogde ziekteactiviteit van de RA tijdens de zwangerschap 
geassocieerd is met een snelle inhaalgroei in gewicht tijdens de eerste drie maanden. 
Deze gevonden associatie was onafhankelijk van het gebruik van medicatie of de 
aanwezigheid van RA geassocieerde antistoffen. Op grond van deze bevinding zou 
verhoogde RA-ziekteactiviteit vermeden moeten worden tijdens de zwangerschap, 
omdat het een verhoogd risico zou kunnen geven op cardiovasculaire en metabole 
aandoening op volwassen leeftijd bij het kind. Medicatie tijdens de zwangerschap, 
inclusief het gebruik van prednison, vertoonde geen relatie met de snelheid van de 
groei van het kind. 
   De conclusie van dit hoofdstuk is dat continueren of uitbreiden van medicatie tijdens 
de zwangerschap met als doel het verlagen van de ziekteactiviteit van de RA de latere 
gezondheid van het ongeboren kind positief zou kunnen beïnvloeden. 
 
 
Hoofdstuk 4 
 
In dit hoofdstuk wordt beschreven hoe het gebruik van medicatie en de ziekteactiviteit 
van RA tijdens de zwangerschap geassocieerd zijn met de botdichtheid van het 
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zwangerschap en het geslacht van het kind. In de kliniek wordt een verschil van 0.5 SDS 
beschouwd als relevant.  
   De studie laat zien dat een verhoogde serumconcentratie van interleukine-10 (IL-10) 
en van interleukine-6 (IL-6) tijdens het eerste trimester van de zwangerschap 
geassocieerd zijn met geboortegewicht van het kind. De gevonden associatie was 
onafhankelijk van de ziekteactiviteit van de RA. In de groep met hoog IL-10 was het 
geboortegewicht SDS 0.75 hoger in vergelijking tot de groep met laag IL-10. In de 
groep met hoog IL-6 was het geboortegewicht SDS 0.50 lager in vergelijk tot de groep 
met laag IL-6. Wanneer beide cytokines tegelijkertijd in een model werden 
geanalyseerd was het effect op het geboortewicht zelfs groter. Zo’n gecombineerd 
model resulteerde in een toename van het geboortegewicht SDS met 0.82 in de groep 
met hoog IL-10 en een afname van het geboortegewicht SDS met 0.58 voor de groep 
met hoog IL-6. Er werd geen relatie gevonden tussen de serumconcentratie van tumor-
necrosis factor-alpha (TNFα) en het geboortegewicht.  
 
 
Hoofdstuk 3  
 
Eerdere studies naar kinderen van gezonde vrouwen hebben laten zien dat een snelle 
inhaalgroei in gewicht tijdens de eerste drie maanden na de bevalling kan leiden tot 
cardiovasculaire en metabole aandoeningen op volwassen leeftijd. Om het effect van 
RA tijdens de zwangerschap op de toekomstige ontwikkeling van het kind te analyseren 
hebben we de inhaalgroei in de eerste drie levensmaanden onderzocht  
   We vonden dat een verhoogde ziekteactiviteit van de RA tijdens de zwangerschap 
geassocieerd is met een snelle inhaalgroei in gewicht tijdens de eerste drie maanden. 
Deze gevonden associatie was onafhankelijk van het gebruik van medicatie of de 
aanwezigheid van RA geassocieerde antistoffen. Op grond van deze bevinding zou 
verhoogde RA-ziekteactiviteit vermeden moeten worden tijdens de zwangerschap, 
omdat het een verhoogd risico zou kunnen geven op cardiovasculaire en metabole 
aandoening op volwassen leeftijd bij het kind. Medicatie tijdens de zwangerschap, 
inclusief het gebruik van prednison, vertoonde geen relatie met de snelheid van de 
groei van het kind. 
   De conclusie van dit hoofdstuk is dat continueren of uitbreiden van medicatie tijdens 
de zwangerschap met als doel het verlagen van de ziekteactiviteit van de RA de latere 
gezondheid van het ongeboren kind positief zou kunnen beïnvloeden. 
 
 
Hoofdstuk 4 
 
In dit hoofdstuk wordt beschreven hoe het gebruik van medicatie en de ziekteactiviteit 
van RA tijdens de zwangerschap geassocieerd zijn met de botdichtheid van het 
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nageslacht in de leeftijd van 5 tot 10 jaar. Een bekende bijwerking van het gebruik van 
prednison is dat het de botdichtheid van de patiënt vermindert. Ook een verhoogde 
ziekteactiviteit is geassocieerd met een verminderde botdichtheid in RA-patiënten. Bij 
sulfasalazinegebruik daarentegen kan een verbetering van de botdichtheid optreden. 
In hoeverre de ziekteactiviteit van de RA of medicatiegebruik van de moeder tijdens de 
zwangerschap van invloed is op de botdichtheid van hun kinderen, is niet bekend. 
   In onze populatie vonden we geen associatie tussen enerzijds prednisongebruik of RA 
ziekteactiviteit van de moeder tijdens de zwangerschap en anderzijds een vermindering 
van de botdichtheid van het kind in de leeftijd van 5 tot 10 jaar. Sulfasalazine liet een 
verbetering zien in de totale botdichtheid van het kind. Gezien het ontbreken van 
nadelige effecten op de botdichtheid bij het kind, is er geen reden is om, vanuit dit 
oogpunt, zwangeren met RA de gangbare medicatie voor hun ziekte te onthouden.  
 
 
Hoofdstuk 5  
 
Om te bepalen of er een verhoogd risico is op cardiovasculair ziektes of type 2 diabetes 
mellitus werd de vetverdeling van het kind gemeten en werd de eventuele 
aanwezigheid van het metabolisch syndroom (MetS) onderzocht. Een kind voldoet aan 
de criteria voor het MetS als van een combinatie van vijf gerelateerde cardiovasculaire 
risicofactoren er drie aanwezig zijn. Deze vijf risicofactoren zijn: abdominale obesitas, 
verhoogde triglyceride, verlaagde high-density lipoproteïne, hoge bloeddruk en een 
verhoogde nuchtere glucose spiegel.  
   De vetverdeling van een kind kan bepaald worden met behulp van antropometrische 
metingen, maar kan ook bepaald worden door middel van een dual-energy X-ray 
absorptiometry-scan, waarbij de totale hoeveelheid vet en de verdeling van het vet 
kunnen worden bepaald. In dit hoofdstuk zijn beide methodes gebruikt om de invloed 
van prednisongebruik en die van de RA ziekteactiviteit tijdens de zwangerschap op de 
lichaamssamenstelling van het nageslacht te onderzoeken.  
   De conclusie van het onderzoek is dat de aanwezigheid op MetS geen relatie heeft 
met prednisongebruik of RA ziekteactiviteit tijdens de zwangerschap. Verder is de 
vetverdeling van de kinderen niet verschillend. Er zijn dus geen vroege aanwijzingen 
voor cardiovasculair ziektes of type 2 diabetes mellitus aanwezig bij het nageslacht van 
vrouwen met RA in de leeftijd van 5 tot 10 jaar. 
 
 
Hoofdstuk 6  
 
In dit hoofdstuk richten we ons op de vraag of prednisongebruik tijdens de 
zwangerschap door vrouwen met RA, de insulineresistentie van hun kinderen op 5-10 
jarige leeftijd beïnvloedt.  


Een voorteken van de insulineresistentie is een verlaagde serumconcentratie van 
adiponectine. Adiponectine is een hormoon dat afgegeven wordt door vetweefsel. De 
insulineresistentie in een kind kan ook worden bepaald met het Homeostasis Model of 
Assessment Insulin Resistance (HOMA-IR). Deze index geeft de verhouding weer tussen 
de nuchtere glucose- en nuchtere insulineserumconcentratie. Gezonden kinderen 
hebben een HOMA-IR van 1.  
   Er werd geen verschil gezien in serumconcentratie van adiponectine tussen de 
kinderen die wel of niet waren blootgesteld aan prednison intra-uterien. Ook was er 
geen verschil in de HOMA-IR index. Zodoende wordt er in dit hoofdstuk  geconcludeerd 
dat prednisongebruik tijdens de zwangerschap geen verhoogde kans op 
insulineresistentie geeft bij het nageslacht als de kinderen 5 tot 10 jaar oud zijn.  
 
 
Hoofdstuk 7 
 
Eerdere studies bij dieren hebben laten zien dat foetale blootstelling aan prednison de 
activiteit van de hypothalamus–hypofyse–bijnier-as (in het Engels: hypothalamic-
pituitary-adrenal-axis; HPA-as) van het nageslacht kan beïnvloeden. Cortisol is één van 
de eindproducten van deze HPA-as. Cortisol kan gemeten worden in het serum, maar 
ook in het speeksel.  
   Om de activiteit van de HPA-as in de kinderen van de FEPRA-studie te analyseren zijn 
er meerdere speekselcortisoltesten gedaan bij de kinderen. Deze afnames waren 4 keer 
gedurende een dag: bij het wakker worden, 30 minuten na het wakker worden, om 
13.00 en vlak voordat de kinderen naar bed gingen.  
   De kinderen die foetaal waren blootgesteld aan prednison hadden een hogere cortisol 
dag-spiegel dan de kinderen die niet waren blootgesteld aan prednison. Het verschil in 
de cortisol waarden was klein. Er waren ook geen klinische kenmerken van verhoogde 
cortisol aanwezig, zoals een hogere body mass index of een hogere bloeddruk.  
   De conclusie van dit hoofdstuk is dat op grond van deze studie er geen reden is om 
zwangere vrouwen het gebruik van prednison te ontraden. Echter, vervolgonderzoek 
naar de effecten van prednison bij kinderen die hieraan intra-uterien zijn blootgesteld  
is van belang. Hierbij is het aan te bevelen om ook kinderen te onderzoeken die aan 
hogere doses prednison zijn blootgesteld dan de kinderen in dit proefschrift. 
 
 
Hoofdstuk 8 
 
In de discussie worden de belangrijkste bevindingen uit de FEPRA-studie herhaald en 
vergeleken met andere bevindingen uit de literatuur. Bovendien worden de klinische 
implicaties van de bevindingen beschreven en worden aanbevelingen voor toekomstig 
onderzoek in dit vakgebied gedaan. 
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ACPA  Anti-Citrullinated Protein Antibody 
AUC  Area Under the Curve 
BMD TB  Bone Mineral Density total body 
BMDLS  Bone Mineral Density lumbar spine 
BMI  Body Mass Index 
BP  Blood Pressure 
CAR  Cortisol Awakening Response 
CRP  C-reactive protein 
CVD  Cardiovascular Diseases 
DAS28  Disease Activity Score of Rheumatoid Arthritis in 28 joints with CRP levels 
DXA  Dual-Energy X-ray Absorptiometry 
ECM  Extracellular Matrix  
FEPRA  FEtal Programming in Rheumatoid Arthritis 
FGIR  Fasting Glucose/Insulin Ratio 
FM  Fat Mass  
HEC  Hyperinsulinemic Euglycemic Clamp  
HDL  High-Density Lipoproteïne  
HOMA-IR Homeostasis Model of Assessment - Insulin Resistance 
HPA  Hypothalamic–Pituitary–Adrenal 
IL-6  Interleukin-6 
IL-10  Interleukin-10 
IQR  Inter Quartile Range 
LBM  Lean Body Mass 
LDL  Low-Density Lipoproteïne  
MetS  Metabolic Syndrome  
MMP-9 Metalloproteinase-9  
OGTT  Oral Glucose Tolerance Test  
PARA   Pregnancy-induced Amelioration of Rheumatoid Arthritis 
PlGF  Placental Growth Factor  
RA  Rheumatoid Arthritis  
RF  Rheumatoid Factor  
SDS   Standard Deviation Score 
T2DM  Type 2 diabetes mellitus  
TG  Triglyceride 
TH   Target Height 
TNFα  Tumor Necrosis Factor-alpha  
VEGF  Vascular Endothelial Growth Factor  
QUICKI  Quantitative Insulin Sensitivity Check Index  
25-OHD 25-hydroxyvitamin D 
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DANKWOORD 
Promoveren is een feest en laat niemand je ooit van iets anders overtuigen. Zoals op elk feest 
begint het rustig en naarmate de avond vordert wordt er meer gedanst en gelachen. Helaas 
kent elk feest ook zijn dode momenten. De muziek is even niet zo leuk. Je bent toch wel moe 
of je wilt gewoon naar huis. Toch weet je dat je door moet. Uiteindelijk gaat de band weer 
iets beters spelen. Je vergeet de pijn aan je voeten. Het wordt een knalfeest. Na de laatste 
dans kijk je terug op een geweldige avond! 
 
Geen feest is compleet zonder muziek. Muziek is de essentie van elk feest, daar waar het 
om draait. Ik wil heel graag alle jongens en meisjes bedanken, die vanuit het hele land 
naar Rotterdam kwamen om vol enthousiasme mee te doen aan de FEPRA studie. Jullie 
waren de muziek van mijn feest, de essentie. 
 
Op elk feest heb je ook eregasten, de zogenoemde VIP’s. Mijn feest kende drie eregasten. De 
mensen die door hun kennis en kunde mij hebben begeleid. Dit zijn mijn promotores prof. dr 
J.M.W Hazes en prof. dr A.C.S Hokken-Koelega en mijn copromotor dr R.J.E.M Dolhain.  
 
Beste Mieke, ik wil je bedanken voor je betrokkenheid met mij persoonlijk en mijn 
onderzoek, maar ook voor de ruimte die je mij hebt gegeven om mijzelf verder te 
ontwikkelen. Jouw passie voor de epidemiologie heeft aanstekelijk gewerkt.  
 
Beste Anita, jouw steun en toewijding in de laatste periode van mijn onderzoek heeft 
mij geraakt. Ik ben je dankbaar voor het vertrouwen dat je in me had. Jouw toewijding 
in het doen en het begeleiden van onderzoek zal mij altijd als voorbeeld dienen. 
 
Beste Radboud, je hebt een fantastische onderzoeklijn opgezet. Ik vond het geweldig 
om daar deel van te mogen zijn. Jij  hebt de afgelopen jaren vaak gesproken over de 
haat-liefde verhouding tussen copromotor en promovendus, maar Radboud, ik ben 
Dolly op je.  
 
Naast de VIP’s zijn er ook de AIP’s, de Also Important People. De mensen die de moeite 
nemen om meer van je proefschrift te lezen dan alleen het dankwoord. De mensen die 
bereid zijn om over de inhoud van het proefschrift van gedachten te wisselen.  
 
Prof. dr E.A.P. Steegers, Prof. dr S.L.S. Drop en Prof. dr T.W.J. Huizinga dank u wel voor 
het plaats nemen in de kleine commissie. Prof. dr A.J. van der Lely, prof. dr W.F. Lems, en 
dr N.M. Wulffraat dank u wel voor het plaats nemen in de grote commissie.   
 
Naast de gasten op het feest is het minstens zo belangrijk dat je een goede DJ hebt, een 
snelle barman en een sterke uitsmijter, kortom de ondersteuning van het feest. 
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De coauteurs van de manuscripten in dit proefschrift dr M.A.J. de Ridder en dr Y.B. de 
Rijke. Beste Maria, dank voor al je geduld bij mijn vragen op het gebied van statistiek. 
Beste Yolanda, dank voor het meedenken van de AKC uitvoering. Prof. dr A.G. 
Uitterlinden en dr F. Rivadeneira dank jullie wel voor alle hulp bij de analyse van de SNP 
data. Ronald en Monique wil ik graag bedanken voor het bepalen van al het bloed en 
speeksel. Jopie Sluimer en collega’s wil ik bedanken voor het uitvoeren en beoordelen 
van alle DEXA-scans die gemaakt moesten worden. En Sander, dank voor al je hulp met 
de Growth Analyser. 
 
Een feest is niet compleet zonder mooie, dansende vrouwen. Het is een algemeen feit dat de 
mooiste meidengroep van het Sophia Kinderziekenhuis, die van de Endo is. 
 
Lieve Annemieke, Elbrich, Gerthe, Judith, Laura, Lidewij, Lin, Manouk, Nienke, Petra, 
Renske, Sinddie, Yvonne en Suzanne (geen Endo maar zeker zo mooi op de dansvloer), 
ik ben jullie dankbaar voor het samen dansen, het samen drinken, het samen zeilen, het 
samen skiën, maar vooral voor het samen delen van zorgen, frustraties en mooie 
momenten. 
 
De mooiste van meidengroep is zonder enig twijfel dr Renes. Lieve Judith, jij was de 
lithium van mijn promotieonderzoek, de alcohol van dit feest. Ik ben je dankbaar voor al 
je steun en vertrouwen and yes Babe, I do love you more than chicken salad. 
 
Waar gedanst wordt, wordt gedronken en dan komen we op dit feest al snel bij de afdeling 
Reumatologie uit.  
 
Lieve Myrthe en Annelieke, ik heb er alle vertrouwen in dat we straks op jullie feestje 
dansen! Dank voor alle jullie steun in moeilijke tijden. Lieve Marie-Louise, dank voor alle 
gezelligheid op de kamer. Pascal, dank je wel voor al je hulp in het begin, en aan het 
einde van mijn onderzoek. Je doet altijd zo stoer, maar ik weet nu wel beter! Verder 
dank aan Martijn, onze STATA-held en David, ons ’liggend’ voorbeeld. Beste Jenny en 
Albert, succes, en wees zuinig op de PARA. Het is een pareltje. 
 
Lieve Anne-Marie, dank voor al het wintersporten in het vriesveem, Nadine en Patrick 
voor alle uren samen onder de zuurkast leidend tot een pipetteerduim en natuurlijk 
Odilia voor het doorlezen en verbeteren van mijn hele manuscript! 
 
Lieve Hetty en Annemarie, het was fijn om te weten dat jullie altijd een beetje over me 
waakten. Zelden kom je zulke lieve mensen tegen in je leven. Lieve Yaël, ik zou nooit 
vergeten de eerste keer dat jij mij wegwijs maakte in de PARA. Jouw kennis en 
toewijding was zo fenomenaal. Jij werd mijn voorbeeld en dat blijf je, als onderzoeker, 
als arts en als persoon. 


En dan natuurlijk die mensen op het feest die eigenlijk niet te gast zijn, want ze horen er 
altijd bij. Je houdt zoveel van ze dat het feest zonder hen wordt afgelast of verplaatst. In mijn 
geval zijn dat mijn ouders, mijn zusje en broertje, mijn Damesch, mijn Biatch, Jacoba’s, 
Takkie en mijn aanstaande. 
 
Lieve ouders, ik ben jullie dankbaar voor het eindeloos geloof in mijn kwaliteiten, voor 
jullie hoop en steun om al mijn dromen waar te maken, maar boven alles voor jullie 
onvoorwaardelijke liefde, die ik al mijn hele leven ken. ”Ons resten geloof, hoop en 
liefde, deze drie, maar de grootste daarvan is de liefde.”(Korinthiërs 13:13) 
 
Lieve Cathelijne, met weemoed denk ik soms terug aan onze tijd in het Amsterdamse, 
de Jacob, de Overtooom. Je bent er altijd voor me geweest en ik ben blij met zo’n een 
fantastische grote zus. 
 
Lieve Jurriaan, wat jij kan, kan ik ook. Het waren niet mijn eerste woorden, maar 
waarschijnlijk wel één van mijn eerste gedachten. Ik ben heel blij dat je straks naast me 
staat, want wat jij kan… 
 
Lieve Laura, Leonie en Muis, al ruim 20 jaar zijn jullie mijn beste vriendinnetjes en ik ben 
zo blij dat jullie er de komende 20 jaar ook weer bij zijn! Of het nu regent of de zon 
schijnt. Jullie zijn er bij elke weersvoorspelling. Lieve Kim, ik ben je dankbaar voor alle 
egeltjes van de afgelopen jaren, de letterlijke en de figuurlijke. Lieve Jacoba’s vamos 
para Rio! Lieve Henrike, geen artikel uit dit boekje is mij zo lief als mijn eerste artikel met 
jou.  
 
Lieve Maurits, jij bent het dierbaarste in mijn leven, nooit meer in me leentje. Ik houd zo 
oneindig veel van je. Samen kunnen we de hele wereld aan, want één plus één is meer 
dan twee. Mijn leven is een feest door jou en we zijn pas bij de openingsdans. 
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Et puis seulement quand c'est fini, alors on danse. 

